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Management of carotid bifurcation stenosis is a cornerstone of stroke prevention and has been the subject of extensive
clinical investigation, includingmultiple controlled randomized trials. The appropriate treatment of patients with carotid
bifurcation disease is of major interest to the community of vascular surgeons. In 2008, the Society for Vascular Surgery
published guidelines for treatment of carotid artery disease. At the time, only one randomized trial, comparing carotid
endarterectomy (CEA) and carotid stenting (CAS), had been published. Since that publication, four major randomized
trials comparing CEA and CAS have been published, and the role of medical management has been re-emphasized. The
current publication updates and expands the 2008 guidelines with specific emphasis on six areas: imaging in identification
and characterization of carotid stenosis, medical therapy (as stand-alone management and also in conjunction with
intervention in patients with carotid bifurcation stenosis), risk stratification to select patients for appropriate interven-
tional management (CEA or CAS), technical standards for performing CEA and CAS, the relative roles of CEA and CAS,
andmanagement of unusual conditions associated with extracranial carotid pathology. Recommendations are made using
the GRADE (Grades of Recommendation Assessment, Development and Evaluation) system, as has been done with other
Society for Vascular Surgery guideline documents. The committee recommends CEA as the first-line treatment for most
symptomatic patients with stenosis of 50% to 99% and asymptomatic patients with stenosis of 60% to 99%. The
perioperative risk of stroke and death in asymptomatic patients must be<3% to ensure benefit for the patient. CAS should
be reserved for symptomatic patients with stenosis of 50% to 99% at high risk for CEA for anatomic or medical reasons.
CAS is not recommended for asymptomatic patients at this time. Asymptomatic patients at high risk for intervention or
with<3 years life expectancy should be considered for medical management as the first-line therapy. (J Vasc Surg 2011;
54:e1-e31.)
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Management of extracranial carotid disease has been
the focus of intense investigation and debate by multiple
medical specialists since the introduction of carotid endar-
terectomy (CEA) as a therapeutic option for the treatment
and prevention of stroke more than half a century ago.
Initial hopes that CEA could reverse the clinical course of
stroke were proven false, and the role of surgical manage-
ment of extracranial carotid and vertebral obstructions was
defined by one of the earliest efforts at a multicentered
randomized clinical trial, The Joint Study on The Extracra-
nial Circulation.1 The results of this decade-long study,
involving 5000 patients, established the role of CEA in the
treatment of minor stroke, transient ischemic attack (TIA),
and amaurosis fugax, confirmed that surgery had a limited aole in the treatment of established stroke, and established
he limited role of vertebral reconstruction in the treatment
f cerebral insufficiency. Over the ensuing decades, surgical
esults of CEA improved, asymptomatic carotid stenosis
as increasingly identified by noninvasive studies, and CEA
ssumed a primarily prophylactic role as prevention of
ajor stroke in asymptomatic patients or those with evi-
ence of transient cerebral or ocular ischemia. Large ran-
omized trials2-6 have established the role and efficacy of
arotid endarterectomy (CEA) in stroke prevention.
In the last decade, carotid artery stenting (CAS) has
merged as a catheter-based alternative to CEA, and med-
cal therapy for stroke treatment and prevention has
volved. Currently, approximately 135,000 interventions
n lesions in the carotid bifurcation are being performed
nnually in the United States, by a variety of specialists,
ncluding vascular surgeons, general surgeons, thoracic sur-
eons, neurosurgeons, cardiologists, interventional radiol-
gists, and interventional neurologists.7,8 Approximately
1% of these interventions are catheter-based, and 90% of
nterventions are in patients without neurologic symp-
oms.7
As in any situation where there are multiple options for
he treatment of a single condition, defining optimal treat-
ent can be difficult. This is further compounded when
ultiple specialists, often with nonoverlapping expertise,
re involved in the treatment of the patient. As a result, a
oluminous and often conflicting literature has developed
round the current standards of diagnosis and management
f extracranial carotid stenosis. Recently two large, pro-
pective, randomized trials have been published comparing
he efficacy of CEA and CAS in the management of ex-
racranial carotid stenosis.9,10 A meta-analysis comparing
AS and CEA, including these trials has recently been
ublished in the Journal of Vascular Surgery.11
In 2008, the Society for Vascular Surgery published
linical practice guidelines for the management of extracra-
ial carotid artery disease in the Journal of Vascular Sur-
ery.12 More recently, a multispecialty document has been
ublished on the “Management of Patients with Extracra-
ial Carotid and Vertebral Artery Disease.”13 This exten-
ive document represents an effort to evaluate the existing
iterature on extracranial carotid and vertebral disease and is
n important reference.
The data contained in the recently published random-
zed trials has prompted the Society for Vascular Surgery to
ublish an update of its 2008 guidelines, confined to man-
gement of extracranial carotid artery disease. This is par-
icularly appropriate because vascular surgeons play a major
f not predominant role in the management of patients with
arotid bifurcation disease.
In developing these recommendations, the committee
laced more weight on the reduction of stroke and death
nd less on the importance of nonfatal myocardial infarc-
ion (MI). Because the latter end point often represents the
ain benefit of CAS, the recommendations in this docu-
ent are more circumspect with regard to the role of CASnd more supportive of the role of CEA than the recom-
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Volume 54, Number 3 Ricotta et al e3mendations of the American Heart Association (AHA)
guidelines committee. This document is divided into six
major sections:
I. Indications for imaging of the extracranial circulation
II. Selection of imaging modality
III. The importance of medical therapy in the overall
management of patients with carotid stenosis, includ-
ing medical management in the peri-intervention pe-
riod.
IV. Technical considerations for performing CEA and
CAS
V. The relative roles of medical management, CEA and
CAS for stroke risk reduction in patients with carotid
stenosis based on review of the literature, with partic-
ular reference to risk factor stratification and the most
recent completed trials
VI. The management of unusual conditions associated
with extracranial carotid pathology, including acute
neurologic conditions, symptomatic carotid occlu-
sion, carotid dissection, and patients with carotid ste-
nosis in need of coronary artery revascularization
The committee reviewed the literature pertinent to
each of the six areas and provided recommendations for
treatment using the GRADE (Grades of Recommendation
Assessment, Development and Evaluation) system.14 This
system, adopted by more than 40 other organizations,
incorporates an evaluation of the strength of the evidence
and the risks/benefits of implementing the recommenda-
tion. For the purposes of this review, we placed the highest
priorities on reducing overall stroke risk, periprocedural
stroke risk, and periprocedural mortality. Lesser impor-
tance was given to reducing nonfatal MI, cost, and the
ability to perform a percutaneous procedure. Recommen-
dations are characterized as strong GRADE 1 or weak
GRADE 2, based on the quality of evidence, the balance
between desirable effects and undesirable ones, the values
and preferences, and the resources and costs.
GRADE 1 recommendations are meant to identify
practices where benefit clearly outweighs risk. These rec-
ommendations can be made by clinicians and accepted by
patients with a high degree of confidence. GRADE 2
recommendations are made when the benefits and risks are
more closely matched and are more dependent on specific
clinical scenarios. In general, physician and patient prefer-
ence plays a more important role in the decision-making
process in these circumstances.
In addition to the GRADE of recommendation, the
level of evidence to support the recommendation is noted.
Evidence is divided into 3 categories: A (high quality), B
(moderate quality), and C (low quality). Conclusions based
on high-quality evidence are unlikely to change with fur-
ther study, those based on moderate-quality evidence are
more likely to be affected by further investigation, and
those based on low-quality evidence are the least supported
by current data and the most likely to be subject to change
in the future. rIt is important to note that a GRADE 1 recommenda-
ion can be made based on low-quality (C) evidence by the
ffect on patient outcome. For example, although there are
ittle data on the efficacy of CEA in asymptomatic patients
ith 60% stenosis, one can recommend with confidence
hat CEA not be performed in these patients. A full expla-
ation of the GRADE system is presented in the recent
rticle by Murad et al14 referenced earlier. It is important to
ote that this grading system differs somewhat from the
ne used in the recent American College of Cardiology
ACC)/AHA Task force report.13
Each member of the committee was assigned responsi-
ility for compiling information pertinent to a specific area
f the document. These data were distributed to all mem-
ers for review, and each area was subsequently discussed in
onference calls. A consensus of the recommendation and
evel of evidence to support it was reached. Each recom-
endation in this document represents the unanimous
pinion of the task force. Although some recommenda-
ions are GRADE 2 with Level 3 data, the task force felt it
ppropriate to present these as the unanimous opinion of its
embers regarding optimal current management. This was
one with the recognition that such recommendations
ould change in the future but that it was unlikely that new
ata would emerge soon. These guidelines are likely to be a
living document” that will change as techniques are fur-
her refined, technology develops, medical therapy im-
roves, and new data emerge.
. INDICATIONS FOR CAROTID
BIFURCATION IMAGING
Stroke is the third leading cause of death, behind
oronary artery disease (CAD) and cancer, and is the lead-
ng cause of disability in the United States and Wes-
ern Europe. Approximately 80% of strokes are ischemic
nd 20% are hemorrhagic.15 Significant carotid stenosis
50%) is seen in 12% to 20% of all anterior circulation
schemic strokes, which is two to three times higher than
he risk for less severe asymptomatic stenosis.16,17 Unfor-
unately, only 15% of stroke victims have a warning TIA
efore stroke, and waiting until symptoms occur is not
deal.18 The purpose of carotid bifurcation imaging is to
etect “stroke-prone” carotid bifurcation plaque and iden-
ify a high-risk patient likely to benefit from therapy de-
igned to reduce stroke risk.
Stroke risk is dependent on many factors, but for pa-
ients with carotid bifurcation disease, the most important
re a history of neurologic symptoms, the degree of stenosis
f the carotid bifurcation plaque, and to a lesser extent,
laque characteristics such as ulcerations, intraplaque hem-
rrhage, and lipid content.
The North American Symptomatic Carotid Endarter-
ctomy Trial (NASCET) and European Carotid Surgery
rial (ECST) clearly demonstrated the efficacy of CEA in
educing stroke in patients with symptoms of carotid terri-
ory cerebral ischemia and carotid bifurcation stenosis that
educed luminal diameter by50%.2-4 In these studies, the
isk of stroke was higher in patients with a clear history of
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September 2011e4 Ricotta et alcarotid territory ischemic events (as opposed to amaurosis
fugax), and stroke risk increased with the severity of steno-
sis. Asymptomatic Carotid Atherosclerosis Study (ACAS)
and Asymptomatic Carotid Surgery Trial (ACST)5,6 found
that CEA was also effective in reducing stroke risk in
patients with asymptomatic carotid stenosis 60%, al-
though the stroke risk inherent in an asymptomatic stenosis
was much less than that in a symptomatic lesion. It follows
then that neurologically symptomatic patients and neuro-
logically asymptomatic patients at high risk for harboring a
carotid stenosis of 60% would be candidates for carotid
bifurcation imaging.
A. Indications for imaging the neurologically
symptomatic patient
Typical carotid territory ischemic symptoms include
contralateral weakness of the face, arm, or leg, or both;
contralateral sensory deficit or paresthesia of the face, arm,
or leg, or both; or transient ipsilateral blindness (amaurosis
fugax). If the right cerebral hemisphere is involved, other
manifestations may be noted, including anosognosia, aso-
matognosia, neglect, visual, or sensory extinction. If the left
hemisphere is involved, patients may show manifestation of
aphasia, alexia, anomia, and agraphesthesia. Symptoms not
typically associated with carotid territory events include
vertigo, ataxia, diplopia, visual disturbances, dysarthria,
nausea, vomiting, decreased consciousness, and weakness,
which may include quadriparesis.
The physical examination may show signs of stroke:
facial/eyelid drooping, motor or sensory deficits, and
speech disturbances. Ocular examinations can occasionally
identify Hollenhorst plaques. Neck auscultation may elicit
carotid bruit; however, the absence of a neck bruit does not
exclude the possibility of a significant carotid bifurcation
lesion. Given the incidence of significant carotid stenosis in
patients who present with stroke15,19 and the effectiveness
of CEA in reducing stroke in symptomatic patients with
50% carotid stenosis,2-4 it is important to evaluate the
carotid bifurcation in every patient with symptoms of ca-
rotid territory ischemia.
Amaurosis fugax or the finding of a Hollenhorst plaque
on funduscopic examination, or both, is also correlated
with the presence of significant carotid bifurcation stenosis.
However, neither amaurosis fugax nor identification of a
Hollenhorst plaque are associated with the same stroke risk
as transient cerebral ischemia.20 Identification of carotid
stenosis in that clinical scenario implies a stroke risk some-
where between a neurologically symptomatic patient and
one who is asymptomatic.
B. Indications for imaging the neurologically
asymptomatic patient
Evaluation and treatment of patients who are neuro-
logically asymptomatic is much more controversial. The
benefit of carotid endarterectomy for stenosis 60%, al-
though statistically significant in large trials, is much less
than for neurologically symptomatic individuals and rests
on the premise that intervention can be performed with tinimal morbidity.5,6 Identification of these asymptomatic
atients may occur by routine screening using duplex ultra-
ound (DUS) imaging or selective application of DUS
maging to high-risk individuals.
1. Screening for asymptomatic carotid stenosis. To
ate, there is no consensus on which patients should un-
ergo carotid screening for the detection of carotid steno-
is. The American Society of Neuroimaging21 concluded
hat the efficacy of screening would be related to the
revalence of the disease in the screened populations. When
he prevalence of stenosis is 20%, screening reduced risk
f stroke in a cost-effective manner, with intermediate
revalence of between 5% and 20%: screening reduced the
isk of stroke in a cost-effective manner in some studies;
owever, the benefit was usually marginal and was lost if
omplications of the intervention 5%. With a prevalence
f5%, screening has not been shown to reduce the risk of
troke in a cost-effective manner and may be harmful.
Given these assumptions, screening of the general pop-
lation is not indicated. This position is supported by
ultiple professional organizations, including the National
troke Association,22 the Canadian Stroke Consortium23
nd the U.S. Preventive Services Task Force.24 The Amer-
can Stroke Association/AHA Stroke Council25 concluded
hat highly selected patient populations may benefit, but
creening of the general population for asymptomatic ca-
otid stenosis was unlikely to be cost-effective and might
ave the potential adverse effect of false-negative or false-
ositive results. Finally, the American College of Cardiol-
gy Foundation, Society for Cardiovascular Angiography
nd Interventions, Society for Vascular Medicine and Biol-
gy, Society of Interventional Radiology, and American
ociety of Interventional & Therapeutic Neuroradiology
linical Expert Consensus Panel on Carotid Stenting rec-
mmended screening for asymptomatic patients with ca-
otid bruit who are potential candidates for carotid inter-
ention and for those in whom coronary artery bypass
rafting (CABG) is planned.26
a. Screening patients with asymptomatic bruit. Zhu
nd Norris,27 in the largest reported study of carotid
creening in asymptomatic patients, reported the preva-
ence of carotid stenosis75% for those with a carotid bruit
as 1.2%. Although the presence of a neck bruit has not
een found to predict carotid stenosis60% in a neurolog-
cally asymptomatic population,27 focal ipsilateral carotid
ruits in neurologically symptomatic patients had a sensi-
ivity of 63% and a specificity of 61% for high-grade carotid
tenosis (range, 70%-99%).28 The absence of a bruit did not
ignificantly change the probability of significant stenosis in
his group of patients (pretest, 52%; post-test, 40%). Ratch-
ord et al29 found in a selected high-risk subgroup of
symptomatic patients that if a bruit was heard, 25% had a
60% stenosis. The presence of carotid bruit has been
hown to increase the absolute risk of stroke,30-32 MI, and
eath.33 In general population-based studies, the preva-
ence of severe bifurcation stenosis is not high enough to
ake bruit alone an indication for carotid screening. Withhese facts in mind, screening should be pursued only if a
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stroke in patients who have a low operative risk5,6,12,34 and
are willing to undergo carotid intervention, whether CEA
or CAS.
b. Potential “high-risk groups” who might benefit from
screening for asymptomatic stenosis. Two studies have
identified specific groups among the general population
with a higher prevalence of significant carotid stenosis that
may30%. Jacobowitz et al35 developed a model identify-
ing patients at high risk for 50% asymptomatic carotid
stenosis. The screened patients were aged 60 years and
had one or more of the following risk factors: history of
hypertension, CAD, current smoking, and a first-degree
family relative with a history of stroke. The prevalence of
carotid artery stenosis was only 2% if no risk factor was
present, 6% with one risk factor, which increased to 14% for
two risk factors, to 16% for three risk factors, and to 67% for
four risk factors.
Qureshi et al36 identified the following variables asso-
ciated with 60% asymptomatic carotid stenosis: age 65
years (odds ratio, 4.1), current smoking (odds ratio, 2),
CAD (odds ratio, 2.4), and hypercholesterolemia (odds
ratio, 1.9). Patients undergoing coronary revascularization
are another group with an increased prevalence of carotid
stenosis of 2% to 27%.37,38 Overall, the prevalence of
carotid artery stenosis among patients undergoing CABG is
higher than the general population. In patients with symp-
tomatic CAD and other risk factors, such as age65 years,
history of stroke or TIA, left main coronary stenosis, dia-
betes mellitus, carotid bruit, peripheral arterial disease
(PAD), and previous carotid operation, it is feasible that a
subset of patients with a prevalence20% can be identified
who might benefit from carotid screening.37,39-45 The
ACC/AHA guidelines46 note that carotid screening before
CABG is probably indicated in the following subset of
patients: age65 years, left main coronary stenosis, history
of smoking, history of TIA/stroke or carotid bruit, and
PAD.
Several studies47-51 have suggested that the prevalence
of60% carotid artery stenosis among patients with symp-
tomatic PAD is 20%, regardless of the patient’s age.
However, the prevalence of 60% carotid artery stenosis
among patients with abdominal aortic aneurysms (AAA) is
20%.52-54 This suggests that screening patients with AAA
would have only a modest benefit and only if intervention
could be performed with low morbidity and mortality.23
Because there is no evidence that stroke risk after AAA
repair is increased by the presence of carotid stenosis,
routine carotid screening of AAA patients is not indicated.
In patients with prior head and neck radiotherapy, the
prevalence of significant carotid artery stenosis may be high
enough, depending on the time between radiotherapy ex-
posure and screening, to justify routine carotid screen-
ing.55-59 The highest incidence is generally observed 15
years after radiotherapy exposure, with 21.3% and 5.3%
rates of ipsilateral and contralateral stenosis, respectively.
The data also suggest that the ipsilateral common carotid
(CCA) and internal carotid arteries (ICA) are both in-olved. The rate of contralateral carotid artery stenosis may
lso be higher than that observed in the general population.
Unfortunately, limited data are available regarding ca-
otid screening after radiotherapy among patients with
ead and neck cancer. However, the distribution of disease
nd clinical course in patients after radiation for head and
eck malignancy is different from that of the typical athero-
clerotic population. There is a higher incidence of diffuse
isease, often involving the CCA, and many of these pa-
ients remain neurologically asymptomatic. Further, CEA
n this group is considered relatively “high risk,” and prior
adiotherapy is a relative indication for CAS rather than
EA. There are no robust data on the long-term results of
AS in asymptomatic stenosis associated with prior radio-
herapy. Therefore, issues other than the increased preva-
ence of disease must be considered in formulating recom-
endations concerning screening in this group of patients.
Brain imaging will occasionally identify patients who
ave evidence of focal cerebral infarction despite the ab-
ence of any history of neurologic symptoms and a normal
esult on the neurologic examination. These infarcts can
ary in size and are often found in the frontal lobes or the
ondominant temporal lobe. They may occur as small
ymmetric lacunar infarcts, implying small-vessel disease, or
hey may also be asymmetric, which tends to implicate
psilateral carotid stenosis. These can be secondary to blood
ow changes distal to carotid occlusion, which may increase
he risk of lacunar infarcts in those with small vessel disease.
owever, Kakkos et al60 reported a higher stroke rate of
.4% vs 1.3% in patients with 60% to 79% clinically asymp-
omatic stenosis if a silent infarct was present. Carotid
creening is recommended in patients with asymptomatic
nfarctions.
● Recommendations for the use of carotid bifurca-
ion imaging
. Imaging of the cervical carotid artery is recommended
in all patients with symptoms of carotid territory isch-
emia. This recommendation is based on the significant
incidence of clinically relevant carotid stenosis in this
patient group and the efficacy of CEA for clinically
significant lesions in reducing overall stroke (GRADE 1,
Level of Evidence A).
. Imaging should be strongly considered for patients who
present with amaurosis fugax, evidence of retinal artery
embolization on funduscopic examination, or asymp-
tomatic cerebral infarction, and are candidates for CEA.
This recommendation is based on the intermediate
stroke risk in this group of patients and the efficacy of
CEA in reducing risk of subsequent stroke (GRADE 1,
Level of Evidence A).
. Routine screening is not recommended to detect clini-
cally asymptomatic carotid stenosis in the general pop-
ulation. Screening is not recommended for presence of a
neck bruit alone without other risk factors. This recom-
mendation is based on the low prevalence of disease in
the population at large, including those with neck
bruits, as well as the potential harm of indiscriminate
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number of asymptomatic individuals (GRADE 1, Level
of Evidence A).
4. Screening for asymptomatic clinically significant carotid
bifurcation stenosis should be considered in certain
groups of patients with multiple risk factors that increase
the incidence of disease as long as the patients are fit for
and willing to consider carotid intervention if a signifi-
cant stenosis is discovered. The presence of a carotid
bruit in these patients increases the likelihood of a
significant stenosis (GRADE 1, Level of Evidence B).
Such groups of patients include:
a. Patients with evidence of clinically significant periph-
eral vascular disease regardless of age.
b. Patients aged 65 years with a history of one or
more of the following atherosclerotic risk factors:
CAD, smoking, or hypercholesterolemia. In general,
the more risk factors present, the higher the yield of
screening should be expected.
5. Carotid screening may be considered in patients before
CABG. This is most likely to be fruitful if the patients
are aged 65 years and have left main disease or a
history of peripheral vascular disease. The strongest
indication for screening these patients from the data
available is to identify patients at high risk for perioper-
ative stroke (GRADE 2, Level of Evidence B).
6. Carotid screening is not recommended for patients with
AAA who do not fit into one of the above categories
(GRADE 2, Level of Evidence B).
7. Carotid screening is not recommended for asymptom-
atic patients who have undergone prior head and neck
radiotherapy. Although the incidence of disease is in-
creased in this group of patients, the utility of interven-
tion in the absence of neurologic symptoms has not
been clearly established (GRADE 2, Level of Evidence B).
II. SELECTING IMAGING MODALITIES FOR
CAROTID EVALUATION
The two most important features of carotid bifurcation
atheroma are the degree of diameter stenosis and the char-
acter of the bifurcation plaque. In addition to information
about the carotid bifurcation, there are clinical scenarios
where the clinician requires information on the status of the
vessels proximal or distal to the cervical carotid artery.
These factors need to be considered when choosing be-
tween imaging studies. It is common—but not universal—
to use multiple modalities when evaluating a patient with
suspected cervical carotid stenosis.
In NASCET2,3 and ECST,4 a higher degree of stenosis
in symptomatic patients was associated with a higher stroke
risk. The ACAS5 found no correlation between the severity
of carotid stenosis and the incidence of stroke; however,
there were too few strokes in this study to permit a sub-
group analysis of the effect of degree of stenosis on the
ability to benefit from CEA. Angiographic data from the
ECST study61 on contralateral asymptomatic carotid arter-
ies from 2295 patients demonstrated a 2% annual stroke
risk in patients with 70% neurologically asymptomatic otenosis. Asymptomatic lesions with greater degrees of
tenosis had a greater risk of stroke: 9.8% for patients with
0% to 79% stenosis and 14.4% for those with 80% to 99%
tenosis. These data suggest that the degree of stenosis is a
arker of stroke risk in symptomatic and asymptomatic
esions. Pathologic studies have demonstrated that more
tenotic carotid plaques are more likely to have ulceration,
ntraplaque hemorrhage, and intraluminal thrombus for-
ation, all of which are clearly related to cerebral emboli-
ation and stroke.62
Plaque morphology is an important feature in assessing
uture risk of neurologic events. Heterogeneous plaques
ave been shown to increase the risk of neurologic symp-
oms (TIA/stroke)63,64 and were also associated with an
ncidence of TIA/stroke that was higher than that in ho-
ogenous plaques for all grades of stenosis.64 Using DUS
maging and computerized image analysis65 quantifying
he gray scale median of the plaque, Biasi et al66 demon-
trated that gray scale median values of25 were associated
ith an increased stroke risk of carotid stenting procedures.
Nicolaides et al67 recently concluded that morphologic
ssessment of plaque structure may allow the identification
f a subgroup of asymptomatic carotid stenoses with a
.5-fold increase in the risk of developing ipsilateral neuro-
ogic symptoms compared with those with a similar degree
f stenosis, which will reduce the number of patients re-
uiring intervention to prevent one stroke. At present,
owever, this type of plaque analysis66,67 is not widely
vailable and requires further prospective evaluation to
etermine its ultimate clinical utility.
The imaging modalities most often used to evaluate
atients for cervical carotid stenosis are carotid DUS
CDUS), magnetic resonance imaging (MRI) and angiog-
aphy (MRA), computed tomography angiography (CTA),
nd digital subtraction angiography (DSA). Each of these
ill be discussed in turn.
. Carotid duplex ultrasound imaging
DUS imaging provides an accurate and reliable nonin-
asive tool to determine the degree of cervical carotid
tenosis and plaque morphology in most patients. It is
sually the initial study in patients who present with symp-
oms or a carotid bruit. Because the study is highly depen-
ent on technique, testing should be done in an accredited
ascular laboratory (eg, Intersocietal Commission for the
ccreditation of Vascular Laboratories), and the images
hould be reviewed by physicians experienced in vascular
ltrasound interpretation.
Determining the degree of carotid artery stenosis is
argely based on an analysis of the peak systolic velocity
PSV) or the end-diastolic velocity (EDV), or both, of the
arotid artery. A panel of experts from several medical
pecialties convened in October 2002 in San Francisco,
alifornia, under the auspices of the Society of Radiologists
n Ultrasound, to arrive at a consensus regarding the per-
ormance of Doppler US imaging to aid in the diagnosis of
CA stenosis.68 This panel of experts recommended a cut-
ff PSV of the ICA of 125 cm/s for predicting angio-
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Volume 54, Number 3 Ricotta et al e7graphic 50% stenosis and 230 cm/s for predicting
70% ICA stenosis. These recommended criteria are based
on an analysis of several published studies and the experi-
ence of the panelists rather than values validated against
other imaging modalities.
AbuRahma et al69 recently analyzed the CDUS and
angiography results of 376 carotid arteries in their institu-
tion. Using the consensus criteria, they demonstrated a
sensitivity of 93%, specificity of 68%, and overall accuracy of
85% for stenosis between 50% and 69%. A PSV of 230
cm/s for70% stenosis had a sensitivity of 99%, specificity
of 86%, and overall accuracy of 95%. Receiver operator
curves showed that the ICA PSV was significantly better
than EDV or ICA/CCA ratio (P  .036) in detecting
70% stenosis and 50% stenosis. There was no improve-
ment in accuracy by adding the EDV values or the ratios, or
both, to the PSV values.
Velocity-based estimation of carotid artery stenosis may
need to be adjusted in certain circumstances, for example,
higher velocities in women than in men and higher veloci-
ties in the presence of contralateral carotid artery occlu-
sion.70,71 High carotid bifurcation, severe arterial tortuos-
ity, extensive vascular calcification, and obesity may also
reduce the accuracy of DUS imaging. Carotid stents will
decrease compliance of the vessel wall and flow velocity.72
DUS imaging may also fail to differentiate between subto-
tal and total carotid occlusion. Intravenous administration
of contrast agents may improve diagnostic accuracy,73,74
but the safety of these agents has been questioned.
Power Doppler and contrast DUS imaging can be used
to differentiate between preocclusive stenosis and complete
occlusion.75 Overall, each vascular laboratory should have
in place an internal validation process of their own criteria
for their internal use.
DUS imaging of the carotid artery has two major
limitations: quality dependence on the technician’s exami-
nation and limitations of visualization of the proximal
carotid artery and intracranial portions. Although the intra-
cranial cerebral arteries can be assessed with transcranial
Doppler imaging, this technique is not as widely available at
most institutions as other imaging modalities.
In addition to determining percent stenosis, DUS, as
noted above, has been used to determine plaque character-
istics (echogenicity) using gray scale median values, which
predict the stroke risk of a particular plaque. Plaque char-
acterization is not routine in every vascular laboratory and
requires specific protocols to assure standardization of re-
sults.
B. Magnetic resonance imaging and angiography
MRA has the advantage of being noninvasive, does not
require iodinated contrast or ionizing radiation, and pro-
vides an unlimited number of projections of the carotid
lumen from a single acquisition. MRA can also assess
intrathoracic and intracranial lesions that are not amenable
to DUS interrogation. MRA does not visualize the sur-
rounding soft tissue structures, unless additional MRI is
performed, and calcium within the plaque is not defined. It cannot be used in patients with implanted ferromagnetic
evices, such as implantable defibrillators and pacemakers,
nd is of limited use in uncooperative patients and those
ith claustrophobia. The gadolinium-based compounds
sed as a contrast agent for MRA have been associated with
ephrogenic systemic fibrosis in patients with pre-existing
enal disorders.76
MRA has a tendency to overestimate the degree of
arotid stenosis. The sensitivity and specificity for diagnos-
ng 70% to 99% stenosis with time-of-flight MRA are
dentical to DUS imaging (88% and 84%, respectively);
owever, MRA has a tendency to “over-read” stenosis,
aking it difficult to differentiate more moderate (50% to
9%) from severe stenosis. Similarly, high-grade stenosis
ill result in a loss of signal on MRA. This does not
epresent a carotid occlusion when the more distal cervical
arotid is visualized. However, when there is no reconsti-
ution of the cervical carotid artery on MRA, the diagnosis
f carotid occlusion can be made with a high degree of
ertainty.76,77
MRI can be used to analyze plaque morphology, spe-
ifically the structure of the atherosclerotic plaque. It can
dentify the lipid-rich necrotic core and the fibrous capsule
ith high sensitivity and specificity78 and can distinguish
etween an intact thick, thin, or ruptured fibrous cap.79
hen dedicated protocols are used, MR also can demon-
trate specific plaque components, including calcium, lipid,
brocellular element, or thrombus within the plaques.
. Computed tomography angiography
CTA is less susceptible than MRA to overestimating the
everity of carotid stenosis. The rapid acquisition of spiral
T images allows excellent timing with contrast adminis-
ration and provides quality images that can be viewed in
ultiple planes. CTA is extremely fast and offers submilli-
eter spatial resolution (0.3 vs 0.8 mm for contrast-
nhanced MRA), is less expensive than contrast-enhanced
RA, provides a faster processing time, and can visualize
oft tissue, bone, and blood vessels at the same time. CTA
an also demonstrate vascular anomalies, has the ability to
uantify the extent of calcification, and can interrogate the
rterial tree from the aortic arch to the circle of Willis.
tenoses can be measured with electronic microcalipers
ased on NASCET or ECST methods.80
A meta-analysis of 28 studies analyzing the diagnostic
ccuracy of CTA compared with DSA showed a pooled
ensitivity of 85% and specificity of 93% for CTA in detect-
ng 70% to 99% carotid stenosis and a sensitivity and spec-
ficity for occlusions of 97% and 99%.81 CTA was also
ighly accurate in identifying calcification but less reliable
n describing carotid plaque morphology, specifically the
ipid component, or ulceration. CTA appears less reliable
han DUS imaging or MRA for assessing plaque morphol-
gy.82 Other limitations of this technique include cost
compared with DUS), contrast exposure, and the added
oncern of radiation exposure. In addition, a large calcium
urden can limit the ability to distinguish contrast from
alcium during postprocessing imaging.
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Many authorities still consider carotid conventional
digital angiography to be the gold standard against all other
imaging modalities in patients with extracranial cerebrovas-
cular disease. Measurement of carotid stenosis using DSA is
generally done using the NASCET method.2 Conventional
angiography is generally reserved for patients with conflict-
ing imaging studies before CEA or in patients considered
for CAS. DSA provides high-quality imaging that is accu-
rate, objective, and easy to interpret. It can identify lesions
from the aortic arch to the intracranial vessels. Major limi-
tations of angiography that make it inappropriate as a
screening modality include its cost and associated risks,
specifically of stroke.83-85 Overall, DSA is most useful in
patients when less invasive imaging studies produce con-
flicting results. When DUS imaging is equivocal, DSA is
preferred over CT and MR in evaluating patients with renal
dysfunction (by minimizing contrast load), obesity, or in-
dwelling ferromagnetic material, which render CTA or
MRA technically inadequate or difficult.
E. Comparison of CDUS, MRA, CTA, and DSA
The U.K. Health Technology Assessment concluded
that although contrast-enhanced MRA was the most accu-
rate imaging modality overall, it was limited by unavailabil-
ity, inaccessibility, and delays. Therefore, they concluded
that color DUS imaging remained the preferred imaging
modality for identifying patients with 70% to 99% steno-
sis.86 As such, CDUS is the preferred imaging modality for
the identification of asymptomatic stenosis.
This recommendation was based on several factors,
including low cost, a much higher number of strokes likely
to be prevented in the long-term by the rapid availability of
CDUS imaging in contrast with other imaging, and the
good sensitivity of imaging in detecting significant stenosis.
However, the Health Technology Assessment highlighted
the concern of the accuracy of DUS in diagnosing 50% to
69% stenosis, which carries a sensitivity of only 36% and a
specificity of 91%.86
The utility of CDUS will depend on the clinical presen-
tation of the patient. In neurologically symptomatic pa-
tients, a diagnosis by CDUS of stenosis between 50% and
69% is sufficient to proceed with surgery based on its
specificity. However, a negative CDUS result would man-
date another imaging study because of the low sensitivity of
CDUS in this setting. In neurologically asymptomatic pa-
tients, a moderate stenosis (50% to 69%) diagnosed by
CDUS should be confirmed by another imaging study
before intervention is undertaken.
F. Imaging after carotid intervention
The prevalence of carotid artery restenosis after CEA
varies between 1% and 37%,87-90 although symptomatic
recurrent stenoses is infrequent (0% to 8%).87 Factors asso-
ciated with restenosis include continued smoking, small
ICA diameter, operative defect detected at intraoperative
assessment, and primary closure after CEA. The aggregatencidence of residual and recurrent carotid stenosis after
EA in ACAS was 13%.88 Of 136 patients who had reste-
osis, 8 (5.9%) underwent reoperation, only 1 of whom was
ymptomatic. There was no correlation between late stroke
nd recurrent stenosis. Similarly, Cao et al89 randomized
353 patients who underwent CEA. Of these, the eversion
echnique was used in 678, and standard CEA with primary
losure was done in 419 and patch closure in 256. The
ife-table estimate of the cumulative risk of restenosis at 4
ears was 4% in the eversion CEA group and 9% in the
tandard CEA group, and 98% of these patients were
symptomatic.
Several studies have reported the progression of con-
ralateral stenosis after CEA.91-93 Contralateral carotid ste-
osis progression was more frequent than ipsilateral recur-
ent stenosis during the long-term follow-up in these
tudies. These studies also identified that the risk of con-
ralateral carotid artery stenosis progression depends on the
xisting disease at the time of the initial CEA.91-93 The risk
f progression for moderate stenosis at the initial surveil-
ance to severe stenosis can be as high as five times.92
Several large prospective studies94-99 have analyzed the
ate of carotid in-stent restenosis after CAS. More patients
ad 70% stenosis of the ipsilateral carotid artery 1 year
fter CAS than after CEA (19% vs 5%). Use of CDUS to
iagnose post-CAS restenosis is confounded by changes in
he velocity criterion caused by the stent itself, and standard
iagnostic criteria do not apply. Artifacts associated with
oth CTA and MRA similarly limit the utility of these
echniques in the post-CAS patient. DSA is required to
onfirm restenosis after CAS identified by CDUS when
eintervention is contemplated. In contrast, CDUS is suf-
cient to diagnose and plan therapy for restenosis after
EA.
● Recommendations for selection of carotid imag-
ng modalities
. CDUS in an accredited vascular laboratory is the initial
diagnostic imaging of choice for evaluating the severity
of stenosis in symptomatic and asymptomatic patients.
Unequivocal identification of stenosis of 50% to 99% in
neurologically symptomatic patients or 70% to 99% in
asymptomatic patients is sufficient to make a decision
regarding intervention (GRADE 1, Level of Evidence A).
. CDUS in an accredited vascular laboratory is the imag-
ing modality of choice to screen asymptomatic popula-
tions at high risk (GRADE 1, Level of Evidence B).
. When CDUS is nondiagnostic or suggests stenosis of
intermediate severity (50% to 69%) in an asymptomatic
patient, additional imaging with MRA, CTA or DSA
is required before embarking on any intervention
(GRADE 1, Level of Evidence B).
. When evaluation of the vessels proximal or distal to the
cervical carotid arteries is needed for diagnosis or to plan
therapy, imaging with CTA, MRA, or catheter angiog-
raphy in addition to CDUS is indicated. CTA is prefer-
able to MRI or MRA for delineating calcium. When
there is discordance between two minimally invasive
H
f
b
r
b
r
a
i
r
J
E
r
a
s
d
p
b
B
g
i
s
R
a
a
U
t
(
V
E
c
r
A
i
l
a
t
t
C
c
w
c
a
l
p
e
s
c
r
a
t
g
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 3 Ricotta et al e9imaging studies (CDUS, MRA, CTA), DSA is indicated
to resolve conflicting results. DSA is generally reserved
for situations where there is inconclusive evidence of
stenosis on less invasive studies or when CAS is planned
(GRADE 1, Level of Evidence B).
5. A postoperative DUS study 30 days is recommended
to assess the status of the endarterectomized vessel. In
patients with 50% stenosis on this study, further
follow-up imaging to assess progression or resolution is
indicated. In patients with a normal DUS study result
and primary closure of the endarterectomy site, ongoing
imaging is recommended to identify recurrent stenosis.
In patients with a normal DUS after patch or eversion
endarterectomy, further imaging of the endarterecto-
mized vessel may be indicated if the patient has multiple
risk factors for progression of atherosclerosis. There are
insufficient data to make recommendations on imaging
after CAS (GRADE 2, Level of Evidence C). Although
the data in this area are not robust concerning intervals
for follow-up imaging, the committee was unanimous in
this recommendation, recognizing that follow-up DUS
carries little risk.
6. Imaging after CAS or CEA is indicated to monitor
contralateral disease progression in patients with con-
tralateral stenosis 50%. In patients with multiple risk
factors for vascular disease, follow-up DUS may be
indicated with lesser degrees of stenosis. The likelihood
of disease progression is related to the initial severity of
stenosis (GRADE 2, Level of Evidence C). Although
the data in this area are not robust concerning intervals
for follow-up imaging, the committee was unanimous in
this recommendation, recognizing that follow-up DUS
carries little risk.
III. MEDICAL MANAGEMENT OF PATIENTS
WITH CAROTID STENOSIS
Optimal medical management is an important part of
overall treatment of all patients with carotid bifurcation
disease, regardless of the degree of stenosis or the plan for
intervention. This therapy is directed both at the reduction
of stroke and overall cardiovascular events, including car-
diovascular-related mortality. The best medical manage-
ment for stroke prevention was highlighted in clinical prac-
tice guidelines issued jointly in 2006 by the AHA and the
American Stroke Association, and cosponsored by the
Council on Cardiovascular Radiology and Intervention and
the American Academy of Neurology.100
A. Treatment of hypertension
Elevated blood pressure increases the risk for stroke,101
and reducing blood pressure decreases the risk for
stroke.102 The relationship between blood pressure and
stroke risk is “continuous, consistent, and independent of
other risk factors.”103 The Framingham Heart study,104
the Atherosclerosis Risk in Communities (ARIC) study,105
and the Cardiovascular Health Study106 each found that
hypertension was independently associated with an ele-
vated risk for carotid artery atherosclerosis. Each 10-mm (g increase in blood pressure results in an increase in risk
or stroke of 30% to 45%. Each 10-mm Hg reduction in
lood pressure amongst hypertensive patients decreases the
isk for stroke by 33%.102
Lowering blood pressure to a target140/90 mm Hg
y lifestyle interventions and antihypertensive treatment is
ecommended in individuals who have hypertension with
symptomatic carotid atherosclerosis.100 Aggressive lower-
ng of blood pressure may harm patients who have had a
ecent stroke by reducing cerebral perfusion. In fact, the
oint National Committee for the Prevention, Detection,
valuation, and Treatment of High Blood Pressure-VII has
emained ambiguous regarding recommendations for
ntihypertensive management in patients with a recent
troke.103 However, antihypertensive therapy aimed at re-
ucing blood pressures to 140/90 is recommended for
atients who have had an ischemic stroke or TIA and are
eyond the hyperacute period.100
. Treatment of diabetes mellitus
In the Cardiovascular Health Study, an elevated fasting
lucose level was associated with an increased risk for stroke
n patients with carotid atherosclerosis.107 The Insulin Re-
istance Atherosclerosis Study108 and the Atherosclerosis
isk in the Community study109 showed that diabetes was
ssociated with intima-media thickness of the carotid artery
nd with progression in intima-media thickness. The
nited Kingdom Prospective Diabetes Study (UKPDS),110
he Action to Control Cardiovascular Risk in Diabetes
ACCORD)111 study, and the Action in Diabetes and
ascular Disease: Preterax and Diamicron MR Controlled
valuation (ADVANCE)112 trial all tested whether tight
ontrol of serum glucose levels in diabetic patients would
educe the risk for stroke. Despite achieving hemoglobin
1C levels6.5%, no reduction in stroke risk was identified
n these trials. Glucose control to nearly normoglycemic
evels (target hemoglobin A1C 7%) is recommended
mong diabetic patients to reduce microvascular complica-
ions and, with lesser certainty, macrovascular complica-
ions other than stroke.
. Treatment of lipid abnormalities
The relationship between elevated cholesterol and in-
ident MI in patients with coronary artery atherosclerosis is
ell established; however, the relationship between hyper-
holesterolemia and incident stroke is less clear. A meta-
nalysis of 45 studies of strokes in patients with hypercho-
esterolemia did not suggest an increased risk for stroke in
atients with elevated serum cholesterol.113 However, sev-
ral other prospective studies in men and women have
ubsequently identified an increase in incident stroke asso-
iated with elevated cholesterol levels.114-116
Patients with known atherosclerosis have demonstrated
educed stroke rates when treated with lipid-lowering ther-
py. The Multiple Risk Factor Intervention Trial of statin
herapy in hypercholesterolemic patients observed that
reater reductions in levels of low-density lipoprotein
LDL) were associated with a reduction in stroke risk. A
P
c
E
i
c
d
T
c
m
a
p
c
A
S
e
a
w
p
c
c
a
t
r
E
o
r
n
w
d
b
w
a
a
C
E
t
R
a
e
p
d
d
t
s
d
d
f
i
l
w
JOURNAL OF VASCULAR SURGERY
September 2011e10 Ricotta et almeta-analysis of 26 trials observed that the risk of stroke
decreased by 15% for every 10% reduction in serum
LDL117 in patients with known coronary or other athero-
sclerosis.
Further meta-analyses of statin trials that also reported
on stroke as an outcome have shown that statin therapy
reduces the risk of stroke by 15% to 30%.118 The Stroke
Prevention by Aggressive Reduction in Cholesterol trial
found that atorvastatin treatment of patients with a recent
stroke or TIA resulted in a reduction in stroke rate by 16%
over 5 years.119
It is less clear if aggressive lipid-lowering therapy results
in regression of carotid artery atherosclerosis. Aggressive
statin therapy in the Measuring Effects on Intima-Media
Thickness: an Evaluation of Rosuvastatin study,120 the
Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol121 study, and the Atorva-
statin vs Simvastatin on Atherosclerosis Progression122
study all showed increased regression of the carotid artery
intima-media thickness compared with controls.
Although LDL is the primary determinant of cardio-
vascular and stroke risk, low levels of high-density lipopro-
tein (HDL) cholesterol also influence stroke risk, and ele-
vation of HDL has been shown to reduce the risk of
stroke.123 In an analysis of a large (9200) series of pa-
tients, treated by dual therapy aimed at decreasing LDL and
raising HDL, elevation of HDL level was independently
associated with a reduction of stroke risk by a factor of 0.86.
Conversely, an elevated total cholesterol/HDL ratio in-
creased stroke risk by a factor of 1.22. Reducing cholesterol
absorption has also been shown to reduce stroke risk in
patients with familial hypercholesterolemia.124 Overall,
however, the HDL level had much less effect on stroke risk
than did the level of LDL.
Elevated cholesterol, comorbid CAD, or evidence of
an atherosclerotic etiology of carotid stenosis should be
managed according to National Cholesterol Education
Program-Adult Treatment Panel III guidelines,125 which
include lifestyle modification or medications, or both. Sta-
tin agents are recommended targeting LDL of 100 mg/
dL, for those with coronary heart disease or symptomatic
atherosclerotic disease, and LDL of 70 mg/dL for very
high-risk persons with multiple risk factors.
D. Smoking cessation
Smoking nearly doubles the risk of stroke.126,127
Smoking also acts synergistically on other risk factors that
are known to increase the risk of stroke, such as CAD and
PAD. Conversely, smoking cessation results in a reduction
in risk for CAD and for coronary mortality.128 Cessation
also reduces the risk of stroke in men and women.128-130
Counseling and smoking cessation medications are effec-
tive in helping smokers to quit. Physician counseling is an
important and effective intervention that reduces smoking
in patients by 10% to 20%131 but continues to be under-
used.132 Nicotine replacement therapy, in the form of
patches and gums, is effective in reducing smoking.133 ratients with extracranial carotid stenosis who are smoking
igarettes should be counseled to quit.
. Antithrombotic treatment
No adequately powered studies have been performed
n asymptomatic patients with carotid atherosclerosis to
onfirm a benefit with antithrombotic treatment in re-
ucing incident stroke. The US Preventative Services
ask Force has recommended daily aspirin as cardiovas-
ular prophylaxis in patients with anticipated cardiac
orbidity of3% for men aged45 years and in women
ged 55 years.134 These recommendations are based
rimarily on an observed reduction in overall cardiovas-
ular morbidity and death with aspirin therapy. The
HA Primary Prevention of Cardiovascular Disease and
troke agrees with this recommendation.135 There is no
vidence to suggest that antiplatelet agents other than
spirin have improved benefit in asymptomatic patients
ith carotid atherosclerosis.
Evidence for antithrombotic treatment for secondary
revention of recurrent stroke in symptomatic patients with
arotid atherosclerosis is more robust.100,136-139 The
hoice of antiplatelet therapy among aspirin, clopidogrel,
nd dipyridamole plus aspirin is not clearly defined because
he data are uncertain.
The Clopidogrel in Unstable Angina to Prevent Recur-
ent Events140 and Clopidogrel for the Reduction of
vents During Observation141 trials each showed a benefit
f clopidogrel plus aspirin compared with aspirin alone in
educing vascular events in patients with prior acute coro-
ary syndromes. The Management of Atherothrombosis
ith Clopidogrel in High-risk Patients142 subsequently
emonstrated no significant difference in vascular events
etween symptomatic patients with carotid stenosis treated
ith clopidogrel plus aspirin compared with clopidogrel
lone.
Clopidogrel alone was initially shown to have a small
dvantage over aspirin in this subset of patients in the
lopidogrel versus Aspirin in Patients at Risk of Ischaemic
vents143 trial. However, it costs more than aspirin, and
he subsequent Clopidogrel for High Atherothrombotic
isk and Ischemic Stabilization, Management, and Avoid-
nce144 trial showed that clopidogrel plus aspirin was
quivalent to aspirin alone in preventing vascular events in
atients with a prior stroke, TIA, or other cardiovascular
isease or in patients with high risk for cardiovascular
isease.
Antiplatelet agents are therefore recommended for pa-
ients with non-cardioembolic ischemic stroke or TIA as-
ociated with carotid atherosclerosis. Aspirin (50-325 mg/
), the combination of aspirin and extended-release
ipyridamole, and clopidogrel, are all acceptable options
or initial therapy; a combination of aspirin and clopidogrel
s not recommended.
Aspirin is currently the most commonly used antiplate-
et agent and one of the most frequently prescribed drugs,
ith as many as 30 million Americans on long-term aspirinegimens. A growing body of evidence suggests that some
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Volume 54, Number 3 Ricotta et al e11patients compliant with aspirin therapy may still develop
atherothrombotic complications, such as stroke. Reduced
antiaggregant effect is more common in patients taking
lower-dose aspirin (81 mg) or 325 mg aspirin with an
enteric coating than it is in patients taking 325 mg of
noncoated aspirin daily.145 The lack of consensus for the
definition of aspirin resistance and for the specific labora-
tory test to identify it has led to large variability in its
reported prevalence.146 The routine laboratory evaluation
of platelet reactivity is not justifiable. The pharmacologic
response to clopidogrel also demonstrates significant inter-
individual variability.
Patients with reduced platelet inhibition in response to
clopidogrel appear to be at increased risk for cardiovascular
events. This resistance may result from reduced bioavail-
ability, polymorphisms of cytochrome P450, additional
genetic variants, or increased platelet turnover.147 Prasug-
rel is an alternate platelet-inhibiting pharmacologic agent
of the same class as clopidogrel that does not have these
limitations. It has been approved for use in acute coronary
syndromes,148 but no data are available on its use for stroke
prevention.
As in the case of aspirin resistance, current evidence
does not suggest the routine use of platelet function or
genetic testing for clopidogrel resistance. In the absence of
randomized trial data, the general approach to patients
developing clinical events while taking aspirin or clopi-
dogrel has been to confirm compliance and increase the
dosage, followed by the addition or substitution of another
antiplatelet agent.149 However, data in this area are insuf-
ficient to allow clear recommendations.
F. Anticoagulant therapy
Parenteral and oral anticoagulants are effective in the
prevention of embolic stroke in patients with atrial fibrilla-
tion or prosthetic heart valves. However, warfarin antico-
agulation has been shown to be less effective than antiplate-
let therapy for secondary prevention of neurologic events in
patients with carotid atherosclerosis who do not have a
history of atrial fibrillation and is not indicated in patients
with symptoms of cerebral ischemia.150,151 The Warfarin-
Aspirin Reduced Cardiac Ejection Fraction Study trial is
currently investigating the potential advantage in prevent-
ing cardioembolic stroke of anticoagulation vs aspirin in
patients with chronic congestive heart failure.152
G. Medical management for the perioperative period
of CEA
Hypertension is a common comorbidity in patients
undergoing CEA. Blood pressure fluctuations, both
above and below normal, are a significant source of
morbidity and may contribute to MI and postoperative
reperfusion syndrome. Careful periprocedural blood
pressure management is critical to obtaining optimal
results from the operation. Although the most recent
AHA guidelines do not classify CEA as a high-risk sur-
gical procedure mandating -blockade, they do indicate
that all patients with known CAD should receive t-blockade therapy before CEA to achieve a stable blood
ressure and heart rate of 60 to 80 beats/min.153,154
iven the near ubiquity of this condition in patients with
arotid stenosis, -blockade is nearly universally required
n this patient group.
Patients taking combined aspirin and clopidogrel ther-
py in the perioperative period have a 0.4% to 1.0% higher
isk of major bleeding compared with aspirin alone.155
spirin therapy alone does not have to be discontinued
efore CEA.156 The risks of periprocedural MI from aspirin
ithdrawal outweigh the risk of fatal or severe bleeding
rom aspirin use. The ACC Perioperative Guidelines en-
orses the continued use of aspirin before and after
EA.153 A low dose (81 to 325 mg) appears at least as
ffective as higher doses, and higher doses may in fact be
ess effective.157 Patients should continue aspirin therapy
fter CEA indefinitely, according to recommendations for
igh-risk patients with atherosclerosis.100,136-139
There has been a consensus that preprocedural clopi-
ogrel should be stopped approximately 5 days before
lective CABG.46 Recent data from a large, retrospective,
ulticentered clinical experience158 suggest that clopi-
ogrel may be safely continued through the perioperative
eriod without increased bleeding risk. It is therefore rea-
onable to individualize the management of perioperative
lopidogrel therapy. There is no clear information regard-
ng the risks or benefits of continued clopidogrel mono-
herapy in the periprocedural period for CEA.
One meta-analysis showed preoperative statin therapy
esulted in a significant reduction in perioperative mortality
n patients undergoing vascular surgery.159 One small ran-
omized trial found that perioperative death, MI, and
troke in patients undergoing vascular surgery was reduced
n the group treated with atorvastatin.160 In one large
bservational study of hospital records of 780,591 patients
ndergoing noncardiac surgery, the risk-adjusted mortality
ate was significantly lower in those who received perioper-
tive statins than in those who were not taking statins (odds
atio, 0.62; 95% confidence interval [CI], 0.58-0.67).161
he evidence for continued use of statin therapy currently
emains largely observational. Furthermore, the optimal
ime for starting therapy, the duration of therapy, dose, or
arget LDL levels to be achieved still remain to be deter-
ined.
. Medical management for the perioperative period
of CAS
Antihypertensive, -blocker, and lipid-lowering ther-
py should be initiated in patients undergoing CAS accord-
ng to the same recommendations for CEA. Patients should
e started on dual antiplatelet therapy with aspirin (325
g) and clopidogrel (75 mg) or ticlopidine (250 mg). No
andomized trial has yet compared CAS performed with
ual-antiplatelet therapy vs aspirin alone. However, the
ublished periprocedural stroke, MI, and death rates in all
ecent clinical trials have been achieved with this combina-
ion therapy.9,10,162,163 Dual-antiplatelet therapy should
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should be continued indefinitely.
● Recommendations for medical management of
patients with carotid atherosclerosis
1. In patients with carotid artery stenosis, treatment of
hypertension, hypercholesterolemia, and efforts at
smoking cessation are recommended to reduce overall
cardiovascular risk and risk of stroke regardless of
whether intervention is planned. Targets are those de-
fined by the National Cholesterol Education Program
guidelines (GRADE 1, Level of Evidence A).
2. Aggressive treatment of hypertension in the setting of
acute stroke is not recommended; however, treatment of
hypertension after this period has passed is associated
with reduced risk of subsequent stroke. The target pa-
rameters are not well defined (GRADE 1, Level of
Evidence C).
3. Treatment of diabetes with the goal of tight glucose
control has not been shown to reduce stroke risk or
decrease complication rates after CEA and is not recom-
mended for these purposes (GRADE 2, Level of Evi-
dence A).
4. Anticoagulation is not recommended for the treatment
of TIA or acute stroke, unless there is evidence of a
cardioembolic source (GRADE 1, Level of Evidence B).
5. Antiplatelet therapy in asymptomatic patients with ca-
rotid atherosclerosis is recommended to reduce overall
cardiovascular morbidity, although it has not been
shown to be effective in the primary prevention of stroke
(GRADE 1, Level of Evidence A).
6. Antiplatelet therapy is recommended for secondary
stroke prevention: aspirin, aspirin combined with dipy-
ridamole, and clopidogrel are all effective. Clopidogrel
combined with aspirin is not more effective than either
drug alone (GRADE 1, Level of Evidence B).
7. Perioperative medical management of patients under-
going carotid revascularization should include blood
pressure control (140/80 mm Hg), -blockade
(heart rate, 60-80 beats/min), and statin therapy (LDL
100 mg/dL) (GRADE 1, Level of Evidence B).
8. Perioperative antithrombotic therapy for CEA should
include aspirin (81-325 mg) (GRADE 1, Level of Evi-
dence A). The use of clopidogrel in the perioperative
period should be decided case-by-case (GRADE 2 Level
of Evidence B).
9. Perioperative antithrombotic management of CAS pa-
tients should include dual-antiplatelet therapy with as-
pirin and ticlopidine or clopidogrel. Dual-antiplatelet
therapy should be initiated at least 3 days before CAS
and continued for 1 month, and aspirin therapy
should be continued indefinitely (GRADE 1, Level of
Evidence C).
IV. TECHNICAL RECOMMENDATIONS FOR
CAROTID INTERVENTIONS
The efficacy of carotid interventions depends on mini-
mizing perioperative complication rates. This involves ap- eropriate risk factor assessment and patient selection,
erioperative therapy, and performance of a technically
xcellent operation. Perioperative therapy and medical
anagement have been discussed in the previous sections.
pecific recommendations on techniques to reduce compli-
ations of CEA and CAS are beyond the scope of this report
nd can be found elsewhere.164,165 However, some general
ecommendations can be made regarding the conduct of
EA and CAS.
. Carotid endarterectomy
Among the variables that have been studied to deter-
ine their effect on the outcome of CEA are local vs
egional anesthesia, routine vs selective use of shunts, mon-
toring of brain function during the procedure, routine
atch closure after endarterectomy, and completion imag-
ng. Although several authors have suggested that use of
egional or local anesthesia is associated with a reduced
ncidence of perioperative hemodynamic changes and car-
iac events, a prospective randomized trial166 and system-
tic review of the literature167 failed to show any difference
etween the two anesthetic approaches.
An abundant literature exists on the indications identi-
ying patients at risk of flow-related ischemia during CEA
nd the role of shunting in reducing this complication.
actors associated with increased risk of cerebral ischemia
uring carotid cross-clamping, and therefore the increa-
ed likelihood that a shunt will be needed, during CEA, in-
lude recent stroke, contralateral carotid occlusion, and
ymptoms suggestive of hemodynamic cerebral insuffi-
iency.168,169 Despite extensive study on the routine or
elective use of shunts and cerebral monitoring during
EA, no clear benefit of one approach over the other has
merged.170
The routine use of completion imaging after CEA also
emains an area of controversy. Although a number of
uthors have reported detecting abnormalities in 5% to 10%
f patients using completion DUS imaging,171,172 and a
ost-benefit analysis suggests completion DUS imaging
ncreases quality-adjusted life-years by 2%,173 the clinical
ignificance of many of these abnormalities is uncertain,
nd several series have reported excellent results without
se of completion imaging.174-176 Like the choice of anes-
hesia and shunting, completion imaging remains a matter
f personal preference.
There are, however, data to recommend the use of
atch angioplasty or eversion endarterectomy over stan-
ard endarterectomy with primary closure. Women and
ndividuals with small ICAs are at most risk of early neuro-
ogic events and late restenosis if standard endarterectomy
ith primary closure is performed. Randomized studies
ave shown the benefit of patch closure over primary
losure in patients undergoing standard CEA.177 The type
f patch material does not appear to have a significant effect
n outcome. Prospective comparisons of eversion CEA
ith primary closure178 have demonstrated a benefit of the
version technique for reduction of early and late stroke.
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restenosis in large single-center reports.179
A number of investigations have studied the relation-
ship of operative volume and specialty training with out-
come. Although data suggest that there is some relation-
ship between operative volume and outcome, the effect
appears less than with other procedures.180 In a large study
of Medicare populations in Maryland and California, sur-
geons who perform 10 to 15 CEAs per year have better
results than those who perform 5 procedures annually,
but there was no added benefit to performing more than
this relatively low threshold. There has been no consistent
relationship between surgical specialty and outcome, and
any effect seen is likely related to volume rather than
specialty designation.8,180,181
B. Carotid artery stenting
The periprocedural management of the CAS patient
has been discussed in a previous section. Periprocedural
antiplatelet therapy is mandatory, and appropriate atten-
tion to access vessels and the status of the aortic arch is
required for optimal results. The technical conduct of the
CAS involves access of the target vessel, crossing the target
lesion, and stent deployment. Technical issues related to
carotid stenting include achieving a stable platform for the
procedure, use of embolic protection devices, stent dilation
before deployment, stent selection, and postdeployment
dilation.
Stable sheath access in the proximal CCA is required.
This depends on appropriate patient selection, as described
above. Once a stable platform is obtained, a decision must
be made about use of a cerebral protection device. In
general, cerebral protection device deployment has been
suggested to reduce the incidence of distal embolization
and, potentially, the risk of stroke.182,183 Although this
position is not supported by robust data, it has been gen-
erally accepted by the medical community, and use of an
embolic protection device has been required by Centers for
Medicare and Medicaid Services to qualify for reimburse-
ment.
Several embolic protection devices are available, and
selection depends on lesion characteristics and anatomic
considerations. Options include proximal or distal occlu-
sion devices designed to interrupt forward flow during the
procedure and filter devices placed distal to the lesion
designed to trap debris released during the procedure.
Distal occlusion devices have the advantage of a smaller
diameter than proximal occlusion devices, but the lesion
must be crossed before the device is placed in the ICA, a
maneuver that can itself cause embolization. At the end of
the procedure, suction is applied between the sheath in the
CCA and the balloon occluding the distal internal carotid
artery to remove debris.
Proximal occlusion devices require placement of two
occlusion balloons, one each in the common and external
carotid artery, with flow reversal by suction or creation of a
proximal arteriovenous connection.184 Placement of a
proximal occlusion device avoids crossing the lesion before brotection is in place and has been associated with the
owest incidence of distal embolization as detected by
ranscranial Doppler imaging or postoperative MRI.184-186
The main procedural disadvantages of the current
roximal occlusion devices are the relatively large size (9F)
f the access sheath, the need to occlude both the common
nd external carotid artery, and the need to establish venous
ccess for continuous flow reversal. Proximal and distal
cclusion devices may both be problematic in patients with
oor intracranial collateral circulation because they man-
ate cessation—and sometimes reversal—of antegrade flow
n the ICA. This situation is generally encountered in 5%
f patients and may be managed by short intermittent
nflation times.
Distal filters are deployed in the distal ICA and trap
ebris released during angioplasty and stent deployment.
ike distal occlusion devices, they have the advantage of a
maller diameter (6F), but the lesion must be initially
rossed in an unprotected fashion. These filters come in a
ariety of configurations and pore sizes. Their efficacy is
elated to the degree with which they can reliably achieve
omplete apposition to the distal arterial wall. They have
he advantage that antegrade ICA flow can be maintained
hroughout the procedure; however, the filter may become
ompletely occluded if large amounts of debris are released,
nd debris may escape distally during filter recapture.
The choice of filter device is often related to individual
reference and familiarity. Some authors believe proximal
cclusion with flow reversal is preferable in nearly all cir-
umstances; however, this technique has its greatest advan-
age in lesions with a high risk of embolization (markedly
rregular plaque, echolucent lesions, active symptoms) or in
hose that may be difficult to cross due to tortuosity or
evere narrowing because protection is in place before the
esion is manipulated. Use of a filter over proximal or distal
cclusion is preferred if there is a likelihood that interrup-
ion of antegrade ICA flow will not be tolerated. Distal
cclusion devices are preferred to filters when the distal
CA anatomy suggests that compete apposition of filter to
he distal ICA wall may be difficult due to size or tortuosity.
Direct comparison of proximal occlusion with flow
eversal vs distal protection shows that proximal protection
ith flow reversal results in the lowest embolic load165,185
owever, no device can completely eliminate the risk of
mbolization during CAS. The fact that no embolic pro-
ection is completely effective and that some emboli origi-
ate during cannulation of the aortic arch and the proximal
reat vessels suggests that although improvements to em-
olization after CAS can be made, the problem cannot be
liminated.
Studies using postoperative diffusion-weighted MRI
hown increased 17% incidence of MRI-identified infarcts
n patients undergoing CAS compared with CEA (adjusted
isk ratio, 5.21).10 Although these are generally subclinical,
ecent reports suggest these lesions might be associated
ith subtle long-term neurologic changes. Echolucent le-
ions are more likely to be associated with increased em-
olic risk, whereas recurrent stenoses or fibrous lesions are
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tion.66,96,165,184
Stent predilation is not recommended unless a filter
cannot be passed. Stent selection is often based on physi-
cian preference. The only large study to test the effect of cell
size suggests that closed-cell stents more effectively con-
strain the carotid plaque and reduce embolization,187 but
there is no consensus on that point. Open-cell stents are
more conformable than closed-cell stents and are preferred
by some in tortuous anatomy. Once the stent has been
deployed, postdilation is used to ensure stent apposition to
the plaque, but vigorous postdilation to achieve anatomic
perfection is avoided.
The learning curve associated with CAS has been the
object of considerable study. The Endarterectomy Versus
Angioplasty in Patients With Symptomatic Severe Carotid
Stenosis162 (EVA-3S) study was criticized because of the
requirement that interventionalists perform only 25 proce-
dures to qualify for participation in the trial. The Carotid
Revascularization Endarterectomy versus Stenting Trial
(CREST) study required a significant lead-in phase for
interventionalists and documentation of low procedural
morbidity.188,189 It is worth noting that CREST is associ-
ated with the lowest periprocedural complication rate in the
literature. There are data in the literature that suggest
achieving a low predictable complication rate after CAS
requires a higher level of initial and ongoing experience
than current guidelines suggest.97,190,191
No relationship has been demonstrated between spe-
cialty and outcome. Data from CREST demonstrate that
vascular surgeons, cardiologists, interventional radiolo-
gists, and interventional neurologists can all achieve com-
parable results with CAS and that experience is more im-
portant than specialty designation in assuring optimal
outcomes.188,189
● Recommendations regarding CEA and CAS tech-
nique
1. Patch angioplasty or eversion endarterectomy are rec-
ommended rather than primary closure to reduce the
early and late complications of CEA (GRADE 1, Level
of Evidence A).
2. Use of an embolic protection device (proximal or distal
occlusion, distal filter) is recommended during CAS to
reduce the risk of cerebral embolization (GRADE 1,
Level of Evidence B).
V. SELECTING THE APPROPRIATE THERAPY:
MEDICAL MANAGEMENT, CAS, OR CEA
Once a patient with a clinically significant carotid ste-
nosis is identified, appropriate treatment must be selected.
Treatment is primarily directed at the reduction of stroke
risk. The risks of an interventional treatment must be
considered when treatment choices are made. In general,
rates of stroke, MI, and death have been used when com-
paring CAS with CEA. In most clinical trials comparing
CAS with CEA, stroke, MI, and death have been given iqual weight in determining a composite end point to test
verall efficacy.
Data from CREST,9 however, indicate that stroke has a
ore significant effect on quality of life at 1 year than
onfatal MI. Because the primary goal of intervention in
arotid stenosis is stroke prevention, in developing its rec-
mmendations, the committee placed more emphasis on
he prevention of stroke and procedurally related death
han the occurrence of periprocedural MI. This may result
n committee recommendations that differ from the pub-
ished results of some trials where these three end points
ere given equal weight in analysis.
Treatment is chosen based on the assessment of risk
ssociated with intervention and the likelihood that a par-
icular intervention will favorably alter the course of the
isease. The major determinants of the clinical course of
atients with carotid bifurcation stenosis are the presence
r absence of neurologic symptoms and the degree of
arotid bifurcation stenosis. The threat of stroke in asymp-
omatic patients with60% ICA stenosis and in symptom-
tic patients with 50% stenosis is generally considered to be
mall and does not warrant intervention. ECST and
ASCET2-4 demonstrated that CEA was unable to reduce
he subsequent neurologic event rates in patients with
ymptoms of cerebral ischemia and bifurcation stenosis of
50% diameter reduction and was actually associated with
ncreased morbidity compared with medical management.
tenoses of 60% diameter reduction were excluded from
he asymptomatic studies,5,6 assuming that asymptomatic
atients with stenosis60% would not benefit from carotid
econstruction. Given the findings of the symptomatic tri-
ls, this proved to be an appropriate decision. There have
een no studies supporting either CEA or CAS for this
ohort of patients.16
. Assessing the risk associated with intervention
CEA and CAS are each associated with specific clinical
cenarios that increase their respective risks. This section
rovides information to identify conditions that pose an
ncreased risk for CAS or CEA and thereby help select the
ost appropriate therapy. When the risk of intervention is
ufficiently increased due to the presence of one or more of
hese factors, medical therapy may be more appropriate
han CEA or CAS.
In the initial CAS trials, a series of anatomic and
hysiologic criteria were developed by a consensus panel
n an attempt to identify “high-risk” CEA patients who
ight be expected to benefit from CAS.192 Although
hese criteria were used to enroll patients in CAS trials
nd registries, their ability to define “high risk” was
ever validated in a prospective manner. In fact, some
ave suggested that CEA could be safely performed in
ost of these patients.193,194 As CAS experience ma-
ured, certain conditions have been shown to be associ-
ted with increased complications after CAS. Risk strat-
fication can generally be divided into two categories:
natomic (including the lesion) characteristics and phys-
ologic characteristics.
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a. Lesion location. CEA provides excellent access to
the cervical carotid artery, but lesions that extend outside
this zone can be difficult to treat surgically. Lesions at or
above the level of the C2 cervical vertebra or below the
clavicle are generally more difficult to expose surgically for
CEA without increasing the morbidity of the operation.
Lesions of the distal cervical carotid artery can be exposed
by division of the digastric muscle and subluxation or
division of the mandible, as required.195,196 Although
rarely required, these high carotid exposures may be asso-
ciated with increased difficulty in directly visualizing the
end point of the endarterectomy and with increased inci-
dence of cranial nerve injury, particularly cranial nerve
IX.195,196 Lesions of the very proximal CCAs are difficult
or impossible to expose without extending the incision into
the chest. This must be considered when evaluating the
morbidity of the procedure.
b. Lesion characteristics. Lesion-specific characteristics
are thought to increase the risk of cerebral vascular events
after CAS66,197 and include a “soft” lipid-rich plaque iden-
tified on noninvasive imaging, extensive (15 mm or more)
disease, a preocclusive lesion, and circumferential heavy
calcification. A recent publication using multivariate logis-
tic regression analysis of a large patient cohort demon-
strated increased periprocedural stroke risk (odds ratios,
2.5-5.6) among patients with lesions 15 mm, excessive
calcification, and ulceration.197 An earlier study has shown
a periprocedural stroke risk (odds ratio, 7.1) among pa-
tients with a lipid-rich plaque treated with CAS.66
The CAS procedure requires manipulation of a wire
and a self-expanding stent through the carotid lesion. Un-
stable plaque increases the risk of embolization during
placement of the wire or stent across the carotid lesion. This
can be reduced, but not eliminated, by using flow-reversal
embolic protection rather than distal filter protection.185
Long segment lesions may require the placement of multi-
ple stents, and this situation and preocclusive stenoses are
both associated with a higher risk of acute or late stent
occlusion. Heavy circumferential calcification makes lesion
dilation more difficult and also increases the risk of embo-
lization with CAS. There are no lesion specific characteris-
tics that increase the risk of CEA.
c. Other anatomic considerations. Several anatomic
situations may increase the difficulty of CEA. These
include reoperation after prior CEA, existence of a cer-
vical stoma, history of neck radiotherapy with resultant
local fibrotic changes of the skin and soft tissues, and
previous ablative neck surgery, such as radical neck dis-
section and laryngectomy.193-195,198
While CEA can be successfully performed in these situa-
tions, particularly when the tissues of the ipsilateral neck are
not scarred and fibrotic, these situations can increase the risk
of wound infection, difficulty of dissection, and potentially,
the incidence of cranial nerve injury. The presence of a short,
thick neck in an obese patient may make dissection more sedious but has not in itself proven to be associated with
ncreased operative risk.
Anatomic factors to consider with CAS are related to
ccess issues. Successful CAS requires remote access of the
CA artery using a stable platform to avoid the intravascular
otion of sheaths, stents, and protection devices during
he procedure. Anatomic factors that may complicate this
rocess include aortoiliac tortuosity, a sharply angulated
ortic arch (type III), or a carotid lesion with more than two
0° bends within a short distance of the target lesion.197
ignificant distal ICA tortuosity may also complicate the
lacement and stabilization of a distal embolic protection
evice. An aortic arch with heavy calcium or a high athero-
clerotic burden is also associated with an increased risk
ith CAS. This is felt to be the main reason that CAS results
re worse in patients aged 80 years.199,200
2. Patient characteristics. It seems intuitive that the
isk of periprocedural events after CEA or CAS might be
ncreased in patients presenting with severe comorbid con-
itions, including dialysis-dependent renal failure, New
ork Heart Association class III or IV heart disease, left
entricular ejection fraction 30%, class III or IV angina
ectoris, left main or multivessel coronary disease, severe
ortic valvular disease, oxygen- or steroid-dependent pul-
onary disease, or both, contralateral carotid occlusion,
nd advanced age. However, little data exist to support one
herapy over another in these patients.162,163 In fact, defin-
ng a high-risk patient is much more subjective than defin-
ng a high-risk lesion.193,194,201,202
As will be seen later, CAS is associated with a lower
ncidence of cardiac events than is seen in CEA. Therefore,
AS would be preferred over CEA when severe cardiac
omorbidities exist in neurologically symptomatic patients.
hronic renal insufficiency has been associated with in-
reased risk of stroke and death after CAS203,204 and
EA.205,206 Univariate and multivariate analysis both show
hat the risk of death, stroke, and MI after CAS at 6 months
as associated with hazard ratios2.5 among patients with
hronic kidney disease.204 Chronic renal insufficiency also
ncreases the risk of stroke after CEA (1.08% to 5.56%).
mong asymptomatic patients with cardiac or renal insuf-
ciency, best medical therapy may be preferable to CAS or
EA. CEA or CAS may be considered among symptomatic
igh-risk patients with moderate to severe carotid stenosis,
ut the effectiveness over medical therapy is not well
stablished.
There are conflicting data on the influence of contralat-
ral occlusion on the outcome of CEA or CAS. NASCET
eported that a contralateral occlusion increased the risk of
troke after CEA from 5.8% to approximately 14%.207
owever, most reports regarding contralateral occlusion
o not bear this observation out, and a meta-analysis of the
iterature suggests a much more modest increase, from
.4% to 3.7%.208,209 This was statistically significant, but
he results remain within the AHA recommended guide-
ines. Several single-center studies have shown excellent
esults in patients with contralateral carotid occlu-
ion.210,211 A possible explanation for this discrepancy is an
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natively, a more consistent technique of intraoperative
management in single-center reports, including, algorithms
for maintaining intraoperative cerebral perfusion, are more
likely to occur in single-center experience than in multicen-
tered studies.
CEA is associated with a lower stroke risk than CAS in
patients aged 80 years.152,161,162 A combined death,
stroke, and MI rate of10% has been seen in octogenarians
treated with CAS.152,161 In the CREST study, CAS was
associated with an increased stroke risk in patients aged
70 years9 and appeared to have a benefit compared with
CEA in patients aged70 years, although no other studies
have reported this association to date.
Because there is a demonstrable incidence of cranial
nerve injury after CEA that is absent after CAS, patients
with a history of a contralateral vocal cord paralysis are at
increased risk with CEA vs CAS; thus, CAS would be
preferred in these patients.
B. Neurologically asymptomatic patients with carotid
artery stenosis of 60% or more
1. CEA for asymptomatic lesions. Patients with
asymptomatic lesions are currently responsible for nearly all
of the carotid interventions performed in the United
States.7 Controlled randomized trials have compared CEA
with best medical therapy, but there are a paucity of data on
the role of CAS in asymptomatic patients. The results of
ACAS5 and ACST6 favored CEA in the management of
these patients. ACAS demonstrated the superiority of CEA
over antiplatelet therapy alone for asymptomatic patients
with carotid stenosis of 60%. This trial recommended
CEA for these patients (aged 80 years) as long as the
expected combined stroke and mortality rate for the indi-
vidual surgeon was not 3%.
The long-term effectiveness of CEA in asymptomatic
patients was confirmed by the recently updated results of
ACST I, as reported by Halliday et al.212 Compared with
the randomized medical arm, where patients primarily re-
ceived antithrombotic and antihypertensive therapy, the
patients in the CEA arm (aged 75 years) experienced
significantly lower perioperative and 10-year stroke rates
(13.3% vs 17.9%). The strength of these conclusions
have been questioned, based on the relatively modest
absolute benefits of CEA and the contention that the
medical therapy arm did not reflect contemporary med-
ical management.213,214
The question of whether modern medical therapy (in-
cluding statins) is equivalent or superior to CEA or CAS has
not yet been addressed by well-designed, appropriately
funded, prospective, multicenter, and randomized trials.
An upcoming multicenter randomized trial designed to
answer the role of modern pharmacologic therapy in the
management of asymptomatic carotid stenosis is the Stent-
Protected Angioplasty in Asymptomatic Carotid Artery
Stenosis (SPACE-II) study,215 which will include best
medical therapy as the third arm of the trial together with
CEA and CAS. pConcerns have also been raised about whether the
esults of the controlled trials could be attained in general
ractice. Critics pointed out that these trials were per-
ormed in centers of excellence and that the patients were
ighly selected. However, subsequent reports on patients
ho would have been excluded from these trials suggest
hat the exclusion criterion did not falsely lower complica-
ion rates. Combined stroke and death rates after CEA in
atients defined as high-risk or eligible for high-risk carotid
egistries varied between 1.4% and 3.6%, well within the
HA guidelines.193,194,210 Similarly, studies of large Na-
ional Surgical Quality Improvement Program, state, and
edicare databases of between 4,000 and 35,000 pa-
ients7,8,176,215 demonstrated stroke and death rates as low
s 2.2% with a maximum of 6.9% (symptomatic patients
nly), suggesting that results that conform to national
uidelines are achievable across large patient populations.
2. CAS in asymptomatic lesions. Very few studies
ave specifically addressed the outcome of carotid stenting
n asymptomatic patients. CAS has been applied in asymp-
omatic patients based on the benefit seen for CEA, with
he expectation that it would be equivalent or superior to
EA because of its less invasive nature. Many studies of
AS have been in the form of “high-risk” regis-
ries.96,97,163,216-219 Others, such as the Carotid and Ver-
ebral Artery Transluminal Angioplasty Study (CAVATAS)
rial not, only had a small overall usage of stents (26%), but
nly 16 of 504 patients (5%) in the study population were
symptomatic.220 A single-institution study by Brook et
l85 comparing CEA with stenting in asymptomatic pa-
ients was also limited by the small number of patients and
he lack of major postprocedural complications in either
roup.221
Another trial that suffered from a limited number of
atients (100 asymptomatic CAS) in addition to lack of
andomization was the Carotid Revascularization using
ndarterectomy or Stenting Systems (CaRESS) study. The
rimary outcomes were not stratified according to the
resence or absence of neurologic symptoms, probably
ecause of the small number of enrollees. The overall
0-day composite of death/stroke/MI was not statistically
ignificantly different for CEA (4.4%) or for CAS (2.1%),
nd noninferiority of CAS was not demonstrated by statis-
ical methodology.222
In 2004, the Stenting and Angioplasty with Protection
n Patients at High Risk for Endarterectomy (SAPPHIRE)
rial, which included “high-risk” patients, 70% of whom
ere asymptomatic, demonstrated that the results of stent-
ng with cerebral protection devices were not inferior to
hose obtained with CEA.94 The primary end point of the
tudy was the 30-day cumulative incidence of death/
troke/MI, which was 5.4% for asymptomatic patients who
nderwent CAS and 10.2% for CEA (P  .20).
The critics of this study raised several important issues,
ncluding the criteria used to define high-risk patients for
EA, the failure to randomize 50% of eligible patients,
he unexpected high incidence of postoperative stroke,
articularly in the asymptomatic patients, and questions
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absolute complication rates of both CAS and CEA in this
study could not be used to justify either intervention in
asymptomatic patients.223,224 Murad et al11 found that
asymptomatic patients accounted for a minority of all pa-
tients entered in 13 trials of CAS vs CEA and that clear
conclusions on the treatment of asymptomatic patients
were not possible.
CREST9 has been the only recent multicenter random-
ized trial that entered a significant number of individuals
(1181 patients) with asymptomatic carotid artery stenosis.
The published results show that although the risk of stroke
with CAS was greater than for CEA in the asymptomatic
patients, this was not statistically significant. The difference
between CAS and CEA in asymptomatic patients for any
periprocedural stroke was 2.5% vs 1.4%, respectively, and
any periprocedural stroke, death, or postprocedural ipsilat-
eral stroke was 2.5% vs 1.4%, respectively. These results for
CAS and CEA were both within the AHA recommended
guidelines.13 In addition, the primary composite end point
of the study that included any periprocedural stroke, death,
MI, or postprocedural ipsilateral stroke was 3.5% for CAS
and 3.6% for CEA (P  0.96). These results are consider-
ably better than any other large study, including ACAS and
ACST for both procedures.225
The CREST results confirm that CEA and CAS can be
done with relatively low complication rates in asymptom-
atic patients when performed by highly experienced practi-
tioners who use their best judgment to select the most
appropriate patient to be entered into the study. This study
provides a benchmark to strive for, but no other large trials
have achieved these results.
Unfortunately, the authors did not record the number
of patients excluded from the study because they were not
considered “good” candidates for any of the proposed
procedures. Thus, the true applicability of CEA and CAS in
the general population is unknown. This observation may
lead one to believe that the CREST results reflect the best
possible selection of candidates for CAS. This is particularly
true when these results are compared with the considerably
worse results presented in SAPPHIRE, the only other
extant trial with a large number of asymptomatic patients.
Data published by the Society for Vascular Surgery
Outcomes Committee demonstrated that real-world CAS
was associated with a significantly higher rate of major
complications than CEA in asymptomatic patients.226 The
30-day outcome analysis of CAS and CEA in 2818 patients
revealed the combined death, stroke, or MI rate for 1450
CAS patients was 4.6% vs 1.97% for 1368 CEA patients.
Other studies of larger databases7,8,201,215 have yielded
similar results.
Further conclusions on the role of intervention in
asymptomatic patients await the results of two additional
randomized prospective studies designed to compare the
early and long-term results of CEA vs CAS and best medical
management: The Carotid Stenting vs Surgery of Severe
Carotid Artery Disease and Stroke Prevention in Asymp-
tomatic Patients (ACT I) and, the Asymptomatic Carotid durgery Trial (ACST-2).227 Results are not expected until
t least 2018.
3. Medical management of asymptomatic carotid
tenosis. There has been an increasing call for trials to
ompare modern medical management of carotid stenosis
ith both CEA and CAS.213,214 This is based on the
elatively modest absolute stroke reduction in both ACAS
nd ACST,5,6 the effect of optimal medical management on
troke risk (see Section III), and the rates of stroke reported
n SAPPHIRE and many carotid stent registries, all of
hich contain a significant number of asymptomatic pa-
ients. Operation for asymptomatic carotid stenosis should
nly be undertaken in good-risk patients where excellent
esults can be documented. In patients with a short life
xpectancy or multiple risk factors, medical management is
ikely to be superior to intervention. As noted, several
tudies have been designed to test the ultimate role of
edical vs interventional management in asymptomatic
arotid disease.
. Neurologically symptomatic patients with 50% or
greater carotid artery stenosis
1. CEA in symptomatic stenosis. NASCET and
CST both demonstrated the benefit of CEA in neurolog-
cally symptomatic patients with carotid stenosis that re-
uced diameter 50%.2-4 NASCET demonstrated an ab-
olute risk reduction in stroke of 17% at 2 years (24% in
edical arm vs 7% in surgical arm) for patients with 70%
arotid stenosis. ECST demonstrated a similar stroke risk in
his group after 3 years in the medical arm, 26.5% with a
troke risk in the surgical group of 7%, an absolute reduc-
ion of 14.9%. In both studies, the risk of stroke in the
edical arm, and therefore the benefit of CEA, increased
ith the degree of stenosis. The results of these trials firmly
stablished CEA as the treatment of choice for patients with
evere carotid stenosis and are widely accepted throughout
he medical community. The benefit of CEA in more
oderate stenosis of 50% to 69% was more moderate—
5.7% stroke after CEA vs 22.2% stroke with medical
herapy at 5 years—but still statistically significant.3 Steno-
es 50% were not benefited by CEA.
2. CAS in symptomatic stenosis. A number of trials
ave examined the role of CAS in the management of
eurologically symptomatic patients with 50% diameter
tenosis. As previously mentioned, SAPPHIRE demon-
trated overall equivalence of CAS and CEA in the manage-
ent of carotid stenosis, although the number of symp-
omatic patients was too small for subgroup analysis.94 Two
arge prospective randomized European trials, EVA-3S162
nd SPACE1,228 examined the role of CAS vs CEA in
eurologically symptomatic patients. EVA-3S showed a
tatistically inferior outcome for CAS compared with CEA
stroke death, 9.5% vs 3.8%) in these patients. This study
as criticized because of the relatively low level of experi-
nce (minimum of 25 CAS cases) required in the CAS arm.
The Stent-Supported Percutaneous Angioplasty of the
arotid Artery versus Endarterectomy (SPACE) trial was
esigned to test “equivalence” between CEA and CAS in
45
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recruitment of 1200 patients due to the futility of proving
equivalence between the two treatments. The rate of death
or ipsilateral stroke at 30 days was 6.84% for CAS and 6.34%
for CEA in 1183 randomized patients. However, the study
was not powered appropriately and failed to show noninfe-
riority of CAS compared with CEA (P  .09).
Subsequently the International Carotid Stenting Study
Trial (ICST),10 which enrolled 1713 patients, demon-
strated an increased stroke risk for CAS (7.7%) compared
with CEA (4.1%) in neurologically symptomatic patients.
This observed difference was significant (P  .002). The
rate of any stroke or death 30 days of treatment in the
stenting group was more than twice the rate the rate
recorded in the endarterectomy group (7.4% vs 3.4%, P 
.0004). In addition, the composite end point of stroke,
death, and MI significantly favored CEA (5.2%) vs CAS
(8.5%; P .006). It is of interest to note that the authors of
this trial highlight the fact that they observed a higher rate
of fatal MIs with CAS than with CEA. This observation has
not been confirmed in other large studies, including
CREST, and in meta-analysis, where the incidence of MI is
higher in the CEA group.11
D. Meta-analysis: CEA vs CAS
Murad et al11 recently completed an updated meta-
analysis of all published trials comparing CEA and CAS in
the management of patients with carotid stenosis. This
analysis included data from the most recently completed
randomized studies, CREST and ICST, which comprised
56% of all reported patients. Their analysis concluded that,
compared with CEA, CAS was associated with a signifi-
cantly reduced risk of perioperative MI (relative risk reduc-
tion [RRR], 0.43) and a significantly increased risk of any
periprocedural stroke (RRR, 1.48). CAS was associated
with an increased risk of periprocedural death (RRR, 1.40)
that did not reach statistical significance. The risk of ipsilat-
eral major stroke did not differ between the two procedures
(RRR, 1.00), although the studies were underpowered to
test this effect.
● Recommendations for selecting therapy
1. For neurologically symptomatic patients with stenosis
50% or asymptomatic patients with stenosis 60%
diameter reduction, optimal medical therapy is indi-
cated. There are no data to support CAS or CEA in this
patient group (GRADE 1, Level of Evidence B).
2. In most patients with carotid stenosis who are candi-
dates for intervention, CEA is preferred to CAS for
reduction of all-cause stroke and periprocedural death
(GRADE 1, Level of Evidence B). Data from CREST
suggest that patients aged 70 years may be better
treated by CAS, but these data need further confirma-
tion.
3. Neurologically asymptomatic patients with60% diame-
ter stenosis should be considered for CEA for reduction of
long-term risk of stroke, provided the patient has a 3- to i5-year life expectancy and perioperative stroke/death rates
can be3% (GRADE 1, Level of Evidence A).
. CEA is preferred over CAS in patients aged70 years
of age, with long (15-mm) lesions, preocclusive
stenosis, or lipid-rich plaques that can be completely
removed safely by a cervical incision in patients who
have a virgin, nonradiated neck (GRADE 1, Level of
Evidence A).
. CAS is preferred over CEA in symptomatic patients with
50% stenosis and tracheal stoma, situations where
local tissues are scarred and fibrotic from prior ipsilateral
surgery or external beam radiotherapy, prior cranial
nerve injury, and lesions that extend proximal to the
clavicle or distal to the C2 vertebral body (GRADE 2,
Level of Evidence B). CEA may be preferable in situa-
tions where ipsilateral tissue planes remain relatively
intact.
. CAS is preferred over CEA in symptomatic patients with
50% stenosis and severe uncorrectable CAD, conges-
tive heart failure, or chronic obstructive pulmonary dis-
ease (GRADE 2, Level of Evidence C). In making this a
GRADE 2 recommendation, the committee recognized
the difficulty in clearly defining this group of individuals,
both in symptomatology and risk assessment, and ac-
knowledged the potential increased role of aggressive
medical management as primary therapy in this high-
risk group.
. Neurologically asymptomatic patients deemed “high
risk” for CEA should be considered for primary medical
management. CEA can be considered in these patients
only with evidence that perioperative morbidity and
mortality is3%. CAS should not be performed in these
patients except as part of an ongoing clinical trial
(GRADE 1, Level of Evidence B).
. There are insufficient data to recommend CAS as pri-
mary therapy for neurologically asymptomatic patients
with 70% to 99% diameter stenosis. Data from CREST
suggest that in properly selected asymptomatic patients,
CAS is equivalent to CEA in the hands of experienced
interventionalists. Operators and institutions perform-
ing CAS must exhibit expertise sufficient to meet the
previously established AHA guidelines for treatment of
patients with asymptomatic carotid stenosis. Specifi-
cally, the combined stroke and death rate must be 3%
to ensure benefit for the patient (GRADE 2, Level of
Evidence B).
I. UNUSUAL CONDITIONS ASSOCIATED
WITH CAROTID STENOSIS
Vascular surgeons will encounter a number of clinical
cenarios where the role of carotid intervention is not well
stablished. Oftentimes the data regarding treatment are
elatively sparse or represent single-center series rather than
rospective randomized trials. These conditions, however,
ay still be associated with the development of cerebral
ymptoms, particularly cerebrovascular accident (CVA)
nd consequently warrant analysis and recommendat-
on.46,229 For the most part, randomized controlled trials
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occur infrequently, and consequently, Level I evidence is
often not available to guide physician practice. Nonethe-
less, the task force members determined that it was appro-
priate to make some recommendations in areas where they
could reach unanimous agreement. These recommenda-
tions should be taken as the best opinion of the task force
given current available data. As stated earlier, they may well
change in the future as therapy evolves and new data
emerge.
A. Acute neurologic syndromes
Acute neurologic syndromes can be divided in to sev-
eral clinical categories: acute stroke, stroke in evolution,
and crescendo TIAs. The pathophysiology and concerns in
each category are somewhat different, as are the treatment
algorithms and outcomes.
Acute stroke is often associated with intracranial
thrombosis, although this is less common in patients with
the other two clinical presentations. As a consequence, a
major management goal is to identify those patients with
intracranial occlusion and to reperfuse the ischemic brain as
rapidly as possible. Therapy is primarily directed at the
intracranial occlusion. Although carotid bifurcation steno-
sis may be present, occlusion of the ICA in the neck is
unusual in patients who are candidates for intervention.
In contrast, patients with crescendo TIA, by definition,
have not had a significant volume of brain infarcted but do
have a significant amount of brain at risk from a very
unstable lesion with multiple small emboli or a large isch-
emic brain penumbra due to hemodynamic compromise
and poor cerebral autoregulation. In these cases attention is
directed at the source of symptoms, usually the carotid
bifurcation.
Patients with stroke in evolution occupy a middle
ground. Often there has been a permanent area of infarc-
tion, but the remaining ischemic penumbra is significant
and attention is directed at salvaging this ischemic area as
rapidly as possible.
In each of these clinical scenarios, expeditious clini-
cal evaluation, brain imaging, and rapid evaluation of the
carotid bifurcation is important in optimizing results.
Brain imaging, most often by diffusion-weighted MRI,
allows a rapid assessment of the amount of brain in-
fracted and the amount at risk, whereas CDUS imaging
can assess the status of the bifurcation. As will be dis-
cussed below, this information dictates the branch points
in treatment algorithms that follow. In general, patients
with preocclusive carotid stenosis or carotid occlusion
are considered for emergency intervention, whereas
those with lesser degrees of stenosis are initially managed
medically with urgent, but not emergency intervention,
according to the recommendations for symptomatic pa-
tients with carotid stenosis.
1. Management of acute stroke.
a. Presentation within 0-6 hours. The National Insti-
tute of Neurological Disorders and Stroke trial established che efficacy of intravenous recombinant tissue plasminogen
ctivator in the treatment of acute stroke, if therapy could
e initiated3 hours of the onset of symptoms.230 Efficacy
as also been established for transarterial intracranial infu-
ion.231 Factors that have been noted to influence results
nclude the extent of hemispheric involvement, time to the
nitiation of therapy, time to reperfusion, age, blood glu-
ose, and female sex.232-235 The most important of these
ppear to be the degree of hemispheric involvement (30%
y volume), time to reperfusion, and age. The more rapidly
ntracranial reperfusion occurred, the better the neurologic
ecovery, with minimal improvement seen if reperfusion
as not established before 6 hours.234 Thrombolysis may
e given by systemic (intravenous) or local (intracranial)
outes, and both routes are used in some cases to facilitate
apid reperfusion.234
Intravenous recombinant tissue plasminogen activator
r-tPA) has the advantage of rapid onset of administration
ut the potential disadvantage of longer time to reperfu-
ion. Administration of r-tPA into the intracranial throm-
us requires assembling a neurointerventional team and
herefore takes longer to implement but is more efficacious
han systemic therapy alone. Data suggest that about 30%
f patients will show neurologic improvement with intra-
enous r-tPA235 and that recanalization will occur in50%
f patients 6 hours when systemic lysis is supplemented
y local intra-arterial infusion.234
Mechanical thrombectomy, ultrasound-facilitated lysis,
nd clot fragmentation or extraction have all been proposed
s methods to accomplish rapid reperfusion without the
ncreased risk of hemorrhage associated with chemical
hrombolysis.236-238 Experience at this time is limited. The
ole of extracranial intervention in the form of CAS or CEA
ust be considered in the context of the treatment of
ntracranial thrombosis or obstruction. Angioplasty and
tenting of the extracranial ICA may be performed as an
djunct to intracranial therapy. Treatment of extracranial
isease offers the potential advantages of preventing further
mbolization from the extracranial carotid atherosclerosis,
ncreasing perfusion to the ischemic penumbra surround-
ng the area of cerebral infarct, enhancing arterial flow to
ugment clot-dissolution therapies, improve access for in-
ervention on the intracranial lesions, and potentially im-
rove the patency of the intracranial intervention. The use
f CAS as an adjunct to intracranial catheter-directed ther-
pies has been evaluated in several case series.239 Although
he results initially reported have been favorable, the overall
xperience has been limited.
b. Presentation later than 6 hours. Only about 15% of
cute stroke patients will present within the 6-hour time
indow for acute intervention.240 Reasons for delay in-
lude failure to recognize symptoms, delay in seeking med-
cal assistance, and a lack of nearby facilities capable of
mergency intervention. As a result, many patients present
utside this therapeutic window. Intervention in these
atients is directed at the carotid bifurcation, not the intra-
ranial circulation, with the goal of preventing recurrent
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cluded arteries.
Patients with an acute fixed deficit of more than
6-hours’ duration and a mild or moderate deficit may be
considered for carotid intervention after a period of medical
stabilization. It is generally accepted that intervention is
safely performed early (2 weeks) after the event and is
preferable to a delayed (4-6 weeks) intervention.241-244
Advances in radiographic imaging have made possible the
identification of a subset of patients who may benefit from
carotid bifurcation intervention in the setting of acute
stroke.245,246
Urgent CEA may be considered for patients in whom
the distal ICA as well as middle cerebral artery and other
intracranial vessels remain patent, who have limited areas of
infarct (30% of hemispheric volume), with significant
areas of ischemic penumbra at risk for progression of the
infarct, have a mild to moderate neurologic deficit, and are
at risk for recurrent embolization and repeat stroke. Pa-
tients should be hemodynamically stable, with mild or
moderate functional deficit, relatively preserved mental sta-
tus, and a favorable prognosis.247-252 Because these are
symptomatic patients, CEA would be recommended unless
the patients are at high risk for surgery due to medical
morbidity or anatomic features.
There are separate groups of patients in whom the
neurologic examination fluctuates under observation.
These patients can be classified as having unstable neuro-
logic syndromes, a category that includes both stroke in
evolution and crescendo TIA. In these clinical syndromes,
urgent or emergent therapy is often considered to reverse
ischemia or salvage brain at risk.
2. Stroke in evolution (fluctuating neurologic defi-
cits). This is a clinical syndrome that has been character-
ized by an evolving neurologic condition associated with an
acute precipitating neurologic event. In these situations,
the initial medical management of stroke, including anti-
platelet agents, volume support, and blood pressure man-
agement, has not succeeded in stabilizing the patient’s
neurologic condition, which may “wax and wane” over the
early course of disease. Although patients may never return
to normal, their neurologic deficits will be mild to moder-
ate in nature. These patients should have brain imaging to
exclude hemorrhage as an etiology and to identify ischemic
but viable brain. Carotid imaging by DUS, CTA, or MRA
should identify a tight lesion in the carotid bifurcation.
The presumption is that optimizing hemispheric blood
flow will improve perfusion to the ischemic hemisphere and
reduce the ultimate extent of neurologic deficit. This must
be balanced by concern that restoring blood flow may
result in hemorrhagic conversion of an infarction or a
reperfusion injury.
There are no large series of patients treated in a stan-
dard manner from which to draw definitive conclusions
regarding optimal therapy. In patients where hemorrhage
has been excluded by brain imaging, some surgeons use a
heparin infusion to try to stabilize these patients and pre-
vent propagation of thrombus as part of their immediate ianagement. Only a few reports have included outcomes
f CEA in patients with stroke in evolution. In general the
troke/death rates range from 9.2% to 26.2%.230,248,250-252
his reflects the heterogenous group of patients and lack of
tandard selection criterion for intervention. There are no
ata on unoperated-on controls for comparison. The lack
f high-quality data on the treatment of stroke in evolution
recludes any clear conclusions on the management of this
roup of patients. There has not been a significant experi-
nce with CAS in these patients, distinct from what is
eferenced above for acute stroke, to draw conclusions.
3. Crescendo TIA. This relatively rare clinical syn-
rome is characterized by repetitive episodes of transient
eurologic ischemia, followed by return to a normal neu-
ologic status. The definition of “crescendo” varies, but
enerally includes multiple repetitive events within a 24-
our period that do not respond to antiplatelet therapy.
igh-grade stenosis of the carotid bifurcation, often with
ssociated ulceration or thrombus, is a common finding.
rain imaging does not reveal a significant area of infracted
rain, and there may or may not be a large ischemic
enumbra. Symptoms are thought to arise from an unstable
arotid plaque with recurrent emboli despite antiplatelet
herapy or from unstable cerebral hemodynamics associ-
ted with the bifurcation lesion.
Therapy in these patients is directed at removing the
ausative lesion at the carotid bifurcation. Again, some
urgeons advocate heparin therapy in the immediate pre-
perative period if intracranial hemorrhage has been ex-
luded, but this is based on personal experience rather than
eported data. Urgent CEA in these patients has been
ssociated with an increased risk of stroke compared with
elective” interventions. Overall, however, the results of
urgery in patients with crescendo TIA are better than that
f stroke in evolution. Systematic reviews of the literature
or crescendo TIA report rates of stroke and death of 6.5%
95% CI, 3.4%-10.4%) and stroke, MI, and death of 10.9%
95% CI, 5.5%-17.9%). The comparable end points for
troke in evolution include stroke and death rates of 16.9%
95% CI, 9.2%-26.2%), and stroke, MI and death rates of
0.8% (95% CI, 13.2%-29.6%).252 Although there are no
ata comparing CAS and CEA in these patients, the pre-
umptive increase in embolic potential of these plaques
uggests that CEA would be preferred to CAS when the
ormer is feasible.
4. Acute postintervention stroke or occlusion. Pa-
ients who undergo carotid intervention may suffer stroke
n the early postintervention period. Treatment aims at
estoring intracranial blood flow to normal levels and de-
ends on identifying the etiology of the stroke. In gen-
ral, treatment decisions should be made as expeditiously
s possible. Stroke that occurs immediately after CEA is
onsidered secondary to a technical defect at the opera-
ive site, until proven otherwise. Other etiologies of
troke in the immediate postoperative period include
mbolization, intraoperative watershed infarction, and
ntracranial hemorrhage.
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site is the most common.253 The status of the endarterec-
tomy site should be determined. In most cases, this can be
done by emergency bedside ultrasound imaging. If throm-
bosis is confirmed, then operative exploration with repair
of the defect is indicated. Early re-exploration of an
occluded endarterectomy site with successful repair may
reduce long-term neurologic sequelae. Although there
are no control groups available for comparison, re-
exploration for symptomatic thrombosis has been asso-
ciated with resolution of neurologic deficit in half to
three-quarters of patients.254-256
If imaging shows the endarterectomy site is patent,
other etiologies should be considered, specifically, distal
embolization or intracranial hemorrhage. Emergency head
CT to exclude hemorrhage is followed by anticoagulation
and angiography, with intracranial intervention according
to acute stroke guidelines. If capability for acute stroke
intervention is not available, then anticoagulation and
blood pressure support is indicated.
Acute stroke complicating CAS may result from embo-
lization to the intracranial circulation during the pro-
cedure, occlusion of the angioplasty and stent site, or
intracranial hemorrhage. Because CAS procedures are per-
formed on patients who are awake, ongoing neurologic
assessment is possible to guide evaluation and manage-
ment. Management of acute, symptomatic intracranial em-
bolization commonly reflects the current standard for in-
tervention for acute stroke, as detailed in the previous
section. Management options, including catheter-directed
intra-arterial thrombolysis, clot dissolution or fragmenta-
tion with evacuation, and potentially, intracranial stenting,
may be used as appropriate.233,236-239,257 In selected cases,
perfusion imaging may also be of utility in determining
which patients will potentially benefit from intracranial
revascularization.245,246
Acute occlusion of the stent has rarely been reported. A
total of 10 cases of stent thrombosis have been reported,
with causes being attributed to the use of inappropriate,
balloon-expandable stents, inadequate antiplatelet or anti-
coagulation therapy, or plaque protrusion through the
stent or technical failure Options for management are
analogous to the techniques used for acute de novo occlu-
sion of the internal carotid artery and include recanaliza-
tion, intra-arterial thrombolysis, and management of the
underlying cause of the occlusion.
● Recommendations for management of acute neu-
rologic syndromes
1. Patients who present 6 hours of the onset of stroke
should be considered for acute intervention to reduce
the ultimate neurologic deficit. Interventions may in-
clude local or systemic thrombolysis (GRADE 1, Level
of Evidence A). The role of endoluminal mechanical
lysis or extraction remains to be defined.
2. Patients who present with fixed neurologic deficit 6-
hours’ duration should be considered for CEA once
their condition has been stabilized. CEA should be uperformed 2 weeks of the neurologic event (GRADE
1, Level of Evidence B).
. Patients who present with repetitive (crescendo) epi-
sodes of transient cerebral ischemia unresponsive to
antiplatelet therapy should be considered for urgent
CEA. The risk of intervention is increased over elective
surgery for neurologic symptoms, but not as much as for
patients with stroke in evolution. CEA is preferred to
CAS in these patients based on the presumptive in-
creased embolic potential of bifurcation plaque in this
clinical situation (GRADE 1 Level of Evidence C).
. For acute stroke after CEA, emergent imaging (ultrasound
or fast CTA) is indicated to evaluate the endarterectomy
site. When imaging suggests thrombosis, is indeterminate,
or not available, immediate operative re-exploration is
indicated (GRADE 1, Level of Evidence B).
. When the endarterectomy site is patent, other modali-
ties such as CT and angiography should be used to
better identify the cause of the stroke. If CT excludes
intracranial hemorrhage, anticoagulation is reasonable
until a definitive decision regarding the appropriate
diagnosis and therapy can be made (GRADE 2, Level of
Evidence C). The committee acknowledged the lack of
robust data in this small group of patients but was
unanimous in its endorsement of this recommendation
based on the data available and the low likelihood that
new data would emerge in the near future.
. No firm recommendations can be made on treatment of
stent thrombosis associated with CAS. It is reasonable
to attempt to restore patency by use of chemical lysis or
clot extraction (GRADE 2, Level of Evidence C). The
committee acknowledged the lack of robust data in this
small group of patients but was unanimous in its en-
dorsement of this recommendation based on the data
available and the low likelihood that new data would
emerge in the near future.
. ICA occlusion with persistent symptoms and
external carotid stenosis
Some patients with documented chronic occlusion of
he ICA may develop recurrent neurologic or ocular symp-
oms. Neurologic symptoms may be secondary to emboli-
ation from the distal aspect of the occluded ICA segment,
ntrinsic disease of the external carotid artery, or from
mbolization from the proximal aspect of the occluded
CA. Ocular ischemia may arise from stenosis of the exter-
al carotid artery.258 These patients may be managed by
ndarterectomy of the common and external carotid artery
ith transection and flush ligation of the ICA to remove the
stump” as a cause of the symptoms.259,260 Alternatively,
ngioplasty and stenting of the external carotid artery has
een used to enhance cerebral perfusion in patients with
xternal carotid stenosis and occlusion of the ICA.261
Oral anticoagulation administration has been used in
he treatment of patients with a stroke associated with
hronic occlusion of the ICA. On meta-analysis, anticoag-
lation resulted in a significant reduction in the incidence
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not affect the recurrent stroke rate.262
● Recommendations for management of symptom-
atic ICA occlusion
1. Patients with known ICA occlusion and persistent ipsi-
lateral neurologic symptoms can be treated by endarter-
ectomy of the common and external carotid artery, with
transection and ligation of the ICA origin. The addition
of oral anticoagulation is likely to reduce the rate of
recurrent CVA (GRADE 1, Level of Evidence C).
C. Carotid dissection
Carotid dissection may occur spontaneously or result
from traumatic or iatrogenic injury. Historically, carotid dis-
section has been treated medically with antiplatelet agents or
anticoagulation. Intervention has largely been reserved for
patients with recurrent neurologic symptoms despite anti-
thrombotic therapy, those who experience cerebral hypoper-
fusion due to hemodynamic effects of the dissection, or those
in whom antithrombotic therapy is contraindicated. Open
surgical therapy may be associated with significant rates of
perioperative CVA and cranial nerve injury. The largest case
series reported a 12.5% rate of combined recurrent stroke and
death and a 58% rate of cranial nerve injury.263
More recently, endovascular techniques, including stent
placement with or without adjunctive angioplasty, have been
evaluated. Relatively few reports have been published on a
small number of patients with dissection.264-266 These initial
results provide some encouragement, with the development
of new or progressive symptoms occurring infrequently. En-
dovascular therapies appear to provide significantly superior
results compared with open surgical approaches, with lower
stroke rates and no cranial nerve injuries.
A comprehensive literature review identified 62 pa-
tients treated by endovascular means. The technical success
rate reported was 100%, and the 1-year patency rate was
100%. The rate of recurrent CVA was 11% with no
deaths.264-266 No large series have been reported, and a
multicenter trial appears to be warranted. With these con-
siderations, endovascular treatment of patients when med-
ical management fails appears to be justified.
● Recommendations for management of carotid
dissection
1. Patients with carotid dissection should be initially
treated with antithrombotic therapy (antiplatelet agents
or anticoagulation) (GRADE 1, Level of Evidence C).
2. Patients who remain symptomatic on medical therapy
may be considered for intervention. Although data are
insufficient to make firm recommendations, the com-
mittee unanimously agreed that balloon angioplasty and
stenting is currently preferred over open surgery after
failed medical management (GRADE 2, Level of Evi-
dence C).
D. Combined carotid and coronary disease
The incidence of concomitant carotid and coronary
atherosclerosis is significant. Patients who have coronary nisease amenable to percutaneous coronary intervention
hould be treated in that manner, followed by treatment of
he carotid stenosis. The presence of carotid disease has
een associated with an increase in the incidence of CVA in
he perioperative period for cardiac surgery. The presence
f a bruit increases the risk of CVA to 1.6% to 5.5%, and the
resence of a carotid stenosis between 50% to 99% increases
he risk to 2.0% to 8.4%.38,46,267 Consequently, the man-
gement of concomitant carotid and coronary disease has
een the subject of considerable study.
For patients experiencing symptoms related to a carotid
tenosis (TIA, CVA), the risk of CVA associated with
ardiac surgery is increased to such a degree that concom-
tant management of the carotid disease is mandatory. Prior
VA or TIA increases the risk of perioperative stroke to
.2% to 8.5%. If bilateral 50% to 99% stenoses are present,
he risk of perioperative CVA increases to 5.2% (95% CI,
%-10.8%). If carotid occlusion is present, the risk of peri-
perative CVA increases to 7% to 12% (95% CI, 2.1%-
1.2%).268-271 Alternative treatments, including combined
EA and CABG, staged CEA and CABG, or CAS and
ABG have all been reported.
A review of the literature to date suggests that CEA,
ollowed by CABG, is associated with the lowest stroke
ate, whereas combined CEA and CABG carries a higher
ortality rate, and delayed CEA is associated with the
owest mortality but the highest stroke rate. Most studies
re retrospective reviews, and there is no evidence that
atient groups are comparable. However, in a meta-
nalysis, Naylor et al269 found that the total stroke/MI/
eath rate associated with any combination CEA and
ABG ranges from 9% to 12%.
In contrast to patients with neurologic symptoms
nd those with severe bilateral carotid bifurcation steno-
is, the management of patients requiring cardiac surgery
n whom unilateral asymptomatic carotid stenosis has
een identified is not established. Documentation of a
ncrease in the perioperative stroke rate in patients un-
ergoing cardiac surgery who have been identified as
aving concomitant carotid disease has been well estab-
ished for decades.272 An increase in the incidence of
VA in the perioperative period for patients undergoing
ardiac surgery has been demonstrated for patients with
carotid bruit, carotid stenosis50%, or a history of TIA
r CVA. Stenoses 70% do not appear to be associated
ith increased stroke.271,273
Unfortunately, the literature is not consistent with
egard to the degree of stenosis reported as “significant” or
he criteria for screening and quantifying stenosis. As a
esult, accurate assessment of the stroke risk associated with
n asymptomatic stenosis in CABG patients is not possible
t this time. It remains uncertain if correction of carotid
isease before cardiac surgery is effective in lowering the
erioperative rate of CVA for those patients. Only two
andomized controlled trials have compared combined
EA/CABG with a strategy of CABG first and delayed
EA in patients with unilateral asymptomatic carotid ste-
osis. Hertzer et al274 demonstrated reduced combined
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Volume 54, Number 3 Ricotta et al e23stroke/death rates for combined CEA/CABG compared
to staged CEA (5.6% vs 17%). The stroke rate associated
with the “unprotected” CABG was 7.4%, compared to a
stroke rate of 2.8% with combined CEA/CABG. Recently,
Illuminati et al275 reported randomizing 185 patients with
unilateral severe (80%) asymptomatic carotid stenosis, in
whom aortic arch disease had been excluded by preopera-
tive CT scan, between “protected” CABG (15 CEA first,
79 combined CEA and CABG) and “unprotected” CABG
with CEA performed at a later time (within 3 months) (91
patients). There were no strokes in the “protected” group,
compared to 7 strokes (3 early, 4 later) in the “unpro-
tected” group. All strokes were ipsilateral to the stenosis
and occurred before CEA was performed. These two re-
ports suggest that patients with asymptomatic unilateral
severe stenosis may benefit from CEA before or with CABG
in centers with considerable experience. However, further
studies are required before a general recommendation can
be made. Other factors, including the specific nature of the
cardiac surgery being performed, length of cardiopulmo-
nary bypass, and the status of the aortic arch, among a
variety of other risk factors, are important in determining
overall stroke risk after CABG.271,276 The best results,
stroke/death rates of 2.2%, have been reported for off-
pump CABG and synchronous CEA, although there is
likely a significant influence of patient selection in these
series.277 It is also possible that the presence of carotid
stenosis is a surrogate marker for stroke risk, rather than a
preventable, direct cause (as evidenced by patients with
unilateral carotid occlusion who exhibit the highest periop-
erative rates of CVA).269
In summary, significant indirect evidence suggests that
treatment of neurologically symptomatic carotid stenosis or
patients with bilateral asymptomatic severe disease may
reduce the incidence of perioperative CVA in patients
undergoing cardiac surgery. The data on treatment of
unilateral asymptomatic stenosis 70% suggest CEA be-
fore or in combination with CABG is reasonable in centers
of excellence but the data at this point are insufficient to
make a firm recommendation. Local results are critical in
determining appropriate therapy.
When coronary intervention can be performed per-
cutaneously, this should precede carotid intervention.
Data indicating trends toward improved outcomes for
simultaneous performance of the surgical procedures at
institutions that manage these conditions regularly are
not sufficiently robust to support a definitive recommen-
dation. More recently, some studies suggested a poten-
tial role for CAS before CABG, with a trend toward
decreased stroke rates in the patients treated with
CAS.278,279 A review of the Nationwide Inpatient Sam-
ple found the risk of perioperative stroke was 62% higher
for combined CEA and CABG (3.9%) compared with
combined CAS and CABG (2.4%), with an OR of 1.62
(95% CI, 1.1-2.5).278
If a sequential strategy is planned, CABG may need to
be deferred for 2 to 4 weeks because of the need for
dual-antiplatelet therapy after CAS. This has resulted inome logistical difficulties in patients who require urgent
oronary revascularization. A meta-analysis of all published
esults280 suggested that the stroke/death rate of 9.1% seen
ith CAS and CABG is not significantly different than the
esults with CEA and CABG. One must conclude that data
re insufficient to support a clear recommendation for
reating patients with unilateral asymptomatic carotid ste-
osis who need CABG.
● Recommendations for management of combined
arotid and coronary disease
. Patients with symptomatic carotid stenosis will benefit
from CEA before or concomitant with CABG. The
timing of the intervention depends on clinical presenta-
tion and institutional experience (GRADE 1, Level of
Evidence B).
. Patients with severe bilateral asymptomatic carotid ste-
nosis, including stenosis and contralateral occlusion,
should be considered for CEA before or concomitant
with CABG (GRADE 2, Level of Evidence B).
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